CN102036692A - 多功能创伤敷料基质及相关方法 - Google Patents
多功能创伤敷料基质及相关方法 Download PDFInfo
- Publication number
- CN102036692A CN102036692A CN2009801128071A CN200980112807A CN102036692A CN 102036692 A CN102036692 A CN 102036692A CN 2009801128071 A CN2009801128071 A CN 2009801128071A CN 200980112807 A CN200980112807 A CN 200980112807A CN 102036692 A CN102036692 A CN 102036692A
- Authority
- CN
- China
- Prior art keywords
- substrate
- wound
- polymer
- wound care
- care dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 75
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 239000012528 membrane Substances 0.000 claims abstract description 12
- 206010052428 Wound Diseases 0.000 claims description 228
- 208000027418 Wounds and injury Diseases 0.000 claims description 227
- 239000000758 substrate Substances 0.000 claims description 199
- 229920000642 polymer Polymers 0.000 claims description 144
- 210000001519 tissue Anatomy 0.000 claims description 57
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
- -1 silicyl Chemical group 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 150000001409 amidines Chemical class 0.000 claims description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 239000001301 oxygen Substances 0.000 claims description 25
- 239000006260 foam Substances 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 17
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 229910052698 phosphorus Inorganic materials 0.000 claims description 17
- 239000011574 phosphorus Substances 0.000 claims description 17
- 229910052711 selenium Inorganic materials 0.000 claims description 17
- 239000011669 selenium Substances 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 239000011593 sulfur Substances 0.000 claims description 17
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 14
- 208000025865 Ulcer Diseases 0.000 claims description 13
- 231100000397 ulcer Toxicity 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000029663 wound healing Effects 0.000 claims description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 150000007942 carboxylates Chemical class 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 210000002615 epidermis Anatomy 0.000 claims description 5
- 229920001059 synthetic polymer Polymers 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 239000004753 textile Substances 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 239000002759 woven fabric Substances 0.000 claims description 3
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010028885 Necrotising fasciitis Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 206010061418 Zygomycosis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000007524 mucormycosis Diseases 0.000 claims description 2
- 201000007970 necrotizing fasciitis Diseases 0.000 claims description 2
- 231100000915 pathological change Toxicity 0.000 claims description 2
- 230000036285 pathological change Effects 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- 201000002282 venous insufficiency Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 abstract description 8
- 239000011159 matrix material Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000008467 tissue growth Effects 0.000 abstract 1
- 239000010408 film Substances 0.000 description 45
- 239000002904 solvent Substances 0.000 description 44
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 239000010409 thin film Substances 0.000 description 23
- 230000004888 barrier function Effects 0.000 description 20
- 239000012530 fluid Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000035876 healing Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000012620 biological material Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 8
- 239000004744 fabric Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 238000005507 spraying Methods 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 241001597008 Nomeidae Species 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000012456 homogeneous solution Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 206010063560 Excessive granulation tissue Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 238000000151 deposition Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000001126 granulation tissue Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 238000004528 spin coating Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 239000004567 concrete Substances 0.000 description 4
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 4
- 229960003461 dezocine Drugs 0.000 description 4
- 238000003618 dip coating Methods 0.000 description 4
- 229960002428 fentanyl Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229960004130 itraconazole Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 4
- 125000002769 thiazolinyl group Chemical group 0.000 description 4
- 208000037816 tissue injury Diseases 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- 102000010180 Endothelin receptor Human genes 0.000 description 3
- 108050001739 Endothelin receptor Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 3
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000002318 adhesion promoter Substances 0.000 description 3
- 125000005133 alkynyloxy group Chemical group 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 230000008822 capillary blood flow Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 229960004022 clotrimazole Drugs 0.000 description 3
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229960003913 econazole Drugs 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 3
- 229960005301 pentazocine Drugs 0.000 description 3
- 238000002205 phenol-chloroform extraction Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229960001807 prilocaine Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 3
- 229960002722 terbinafine Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 229960000707 tobramycin Drugs 0.000 description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ZSTLPJLUQNQBDQ-UHFFFAOYSA-N azanylidyne(dihydroxy)-$l^{5}-phosphane Chemical compound OP(O)#N ZSTLPJLUQNQBDQ-UHFFFAOYSA-N 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229960002206 bifonazole Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 2
- 229960005074 butoconazole Drugs 0.000 description 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 2
- 229960001113 butorphanol Drugs 0.000 description 2
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000007766 curtain coating Methods 0.000 description 2
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 229960001274 fenticonazole Drugs 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000010231 histologic analysis Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 229960004849 isoconazole Drugs 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960003406 levorphanol Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229960004313 naftifine Drugs 0.000 description 2
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 2
- 229960000805 nalbuphine Drugs 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960002950 novobiocin Drugs 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229960003483 oxiconazole Drugs 0.000 description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005118 oxymorphone Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002607 sulconazole Drugs 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229960000580 terconazole Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229960004214 tioconazole Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- XEQLFNPSYWZPOW-NUOYRARPSA-N (2r)-4-amino-n-[(1r,2s,3r,4r,5s)-5-amino-4-[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)O)NC(=O)[C@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N XEQLFNPSYWZPOW-NUOYRARPSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- URLVCROWVOSNPT-XOTOMLERSA-N (2s)-4-[(13r)-13-hydroxy-13-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2h-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 URLVCROWVOSNPT-XOTOMLERSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- UPNNXUSUOSTIIM-UHFFFAOYSA-N 1,2-dithietane Chemical compound C1CSS1 UPNNXUSUOSTIIM-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical class C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N 1-Pyrroline Chemical compound C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 1
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- APBSKHYXXKHJFK-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]acetic acid Chemical compound OC(=O)CC1=CSC(C=2C=CC(Cl)=CC=2)=N1 APBSKHYXXKHJFK-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- NRSJYUSYBNFGAK-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Br NRSJYUSYBNFGAK-UHFFFAOYSA-N 0.000 description 1
- KFGWEMFTDGCYSK-UHFFFAOYSA-N 3-methyl-1,2-thiazole 1-oxide Chemical compound CC=1C=CS(=O)N=1 KFGWEMFTDGCYSK-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229930183180 Butirosin Natural products 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical class O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- 239000005795 Imazalil Substances 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229930183998 Lividomycin Natural products 0.000 description 1
- 229930184158 Maridomycin Natural products 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- LOEBNUYIWNXXQK-UHFFFAOYSA-N N1C=CC=C1.[P] Chemical class N1C=CC=C1.[P] LOEBNUYIWNXXQK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- BFMSYFIBEHZDLH-UHFFFAOYSA-N O1NC=CC=C1.S1CC=CC=C1 Chemical compound O1NC=CC=C1.S1CC=CC=C1 BFMSYFIBEHZDLH-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229930186799 Sorbistin Natural products 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FFXJTOKFQATYBI-RUTGJBPVSA-N [(1s,3r,7r,8s,9s,10r,12r,13r,14e,16s)-9-[(2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-[(2s,4r,5s,6s)-4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-13-hydroxy-8-methoxy-3,12-dimethyl-5-oxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1 Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C[C@@H]3O[C@H]3/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C FFXJTOKFQATYBI-RUTGJBPVSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- QUHYUSAHBDACNG-UHFFFAOYSA-N acerogenin 3 Natural products C1=CC(O)=CC=C1CCCCC(=O)CCC1=CC=C(O)C=C1 QUHYUSAHBDACNG-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 108700029371 albomycin Proteins 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical class C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940024554 amdinocillin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003200 azlocillin sodium Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- 229950004527 butirosin Drugs 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940097598 citanest Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960002042 croconazole Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical group O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- URLVCROWVOSNPT-QTTMQESMSA-N desacetyluvaricin Natural products O=C1C(CCCCCCCCCCCC[C@@H](O)[C@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 URLVCROWVOSNPT-QTTMQESMSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960004060 dicloxacillin sodium Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-M dicloxacillin(1-) Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229940099212 dilaudid Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 229960002125 enilconazole Drugs 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950011481 fenclozic acid Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229950007979 flufenisal Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- GSTNAAOCEHQZDY-UHFFFAOYSA-N formic acid phosphane Chemical compound [PH4+].[O-]C=O GSTNAAOCEHQZDY-UHFFFAOYSA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229950010931 furofenac Drugs 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229910021474 group 7 element Inorganic materials 0.000 description 1
- 125000004996 haloaryloxy group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XHILEZUETWRSHC-NRGUFEMZSA-N hydromorphone hydrochloride Chemical compound [H+].[Cl-].O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XHILEZUETWRSHC-NRGUFEMZSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 229940095970 imodium Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229950003076 lividomycin Drugs 0.000 description 1
- DBLVDAUGBTYDFR-SWMBIRFSSA-N lividomycin A Chemical compound O([C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@H]1O)O[C@H]1O[C@H]([C@H]([C@H](O)[C@H]1N)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CN)[C@H]1O[C@H](CO)[C@@H](O)C[C@H]1N DBLVDAUGBTYDFR-SWMBIRFSSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 description 1
- 229950001846 mabuprofen Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 229950002784 maridomycin Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 description 1
- 229960004056 methdilazine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- UWAJGPKPIKRBHZ-BOPCDOEQSA-N n-[(2s,3s,4s,5r,6r)-6-[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](CO)O[C@H](O[C@H]([C@@H](O)CN)[C@H](N)[C@H](O)CO)[C@H](O)[C@H]1O UWAJGPKPIKRBHZ-BOPCDOEQSA-N 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- RHBRMCOKKKZVRY-ITLPAZOVSA-N naltrexone hydrochloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 RHBRMCOKKKZVRY-ITLPAZOVSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940065778 narcan Drugs 0.000 description 1
- 229940029571 naropin Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical class CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XJLMYGIRBIFLGK-UHFFFAOYSA-N pentane;thiophene Chemical compound CCCCC.C=1C=CSC=1 XJLMYGIRBIFLGK-UHFFFAOYSA-N 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229940116238 revex Drugs 0.000 description 1
- 229960003485 ribostamycin Drugs 0.000 description 1
- 229930190553 ribostamycin Natural products 0.000 description 1
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 description 1
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- IUPCWCLVECYZRV-JZMZINANSA-N rosaramicin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IUPCWCLVECYZRV-JZMZINANSA-N 0.000 description 1
- 229950001447 rosaramicin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- HJKXMQLJTKUBMG-INVUDJPSSA-N seldomycin Chemical class N[C@H]1[C@@H](N)[C@H](OC)CO[C@@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)C[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N HJKXMQLJTKUBMG-INVUDJPSSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002911 sialidase inhibitor Chemical class 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940012890 sublimaze Drugs 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 229960000373 tazobactam sodium Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000003553 thiiranes Chemical class 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229950006150 tioxaprofen Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229940003694 ultiva Drugs 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940000146 vicodin Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical class CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了各种不同的实施方案,涉及能够在创伤部位处保护并促进新组织生长的多功能创伤护理敷料基质。多功能创伤护理敷料基质可以掺入式I的聚磷腈,作为能够被构造成各种不同形式的成分,包括作为纤维性垫、多孔膜、无孔薄膜、颗粒制剂和等效物。本公开的多功能创伤护理敷料基质表现出由式I的聚磷腈所赋予的高性能性质。式I的聚磷腈的杰出的生物相容性质为所关注的多功能创伤护理敷料基质提供了理想的组织接触表面。
Description
与相关申请的参考
本申请要求2008年2月22日提交的美国临时专利申请No.61/030,707在35U.S.C.§119(e)下的权益,所述临时专利申请在此以其全文引为参考。
技术领域
本公开涉及掺入和/或包封有聚磷腈聚合物、可以改进各种类型创伤的护理和治疗的各种物品/装置,以及相关的方法。
背景技术
已经开发了各种不同的物品和装置用于管理组织受伤或创伤的护理和治疗。创伤容易受到初始组织受伤后发生的许多继发性效应的影响,包括进一步的机械外伤、病原性浸润、感染、脱水、过量流体外排、败血症、炎症、化脓、瘢痕组织形成、健康组织硬化和/或组织坏死。在创伤部位选择适合具体组织损伤类型的恰当创伤敷料,能够明显促进愈合过程,减少继发性效应包括瘢痕形成和疼痛。许多敷料能够粘连到脆弱的新生表皮层表面,在可能需要经常更换敷料时,能够导致大范围的组织瘢痕形成。创伤护理不充分能够显著降低愈合速度,促进其他继发性并发症例如感染,并引发附加的不适和疼痛。非常需要能够表现出多功能性质的高性能创伤敷料来治疗各种不同类型的人类和动物创伤。
发明概述
各种不同的实施方案涉及能够在创伤部位处保护并促进新组织生长的多功能创伤护理敷料基质(“MFWDM”)。多功能创伤护理敷料基质可以掺入式I的聚磷腈作为能够构造成各种不同形式的成分(component),包括作为纤维性/非纤维性垫、多孔/无孔膜、多孔/无孔薄膜、开孔/闭孔泡沫、用于喷涂施加的颗粒制剂、这些形式的等效物及其组合。式I的聚磷腈表现出范围广泛的独特化学和物理性质,能够掺入到在本公开中被视为多功能创伤护理敷料基质(“MFWDM”)的多种多样创伤护理产品中这:作为主要结构成分、包封另一种结构成分的包层、和/或支持各种非结构性功能的介导成分。将式I的聚磷腈掺入到目标MFWDM的构造中能够提供显著的优点,来促进给定创伤部位的最佳愈合。
附图说明
图1是作为本公开的一个实施方案,能够掺入到多功能创伤护理敷料基质中的一片设想的基材层的示意图。
图2是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质的示意图。
图3是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质的示意图,并包含囊。
图4是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质的示意图,并包含制成泡沫/海绵的式I的聚合物。
图5是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质的示意图,并制成粘附性创伤贴片。
公开内容的详细描述
A.定义
除了下面提供的术语定义之外,没有数量指示的名词意味着一个或多个所指称的标的物。
术语“基材层”包括任何材料,包括各种不同的天然材料、合成聚合物材料及其组合。在各种不同的实施方案中,基材层掺有式I的聚合物。在各种不同的实施方案中,基材层被式I的聚合物部分或全部包封。在其他实施方案中,掺有式I聚合物的基材层包括组织接触表面。在其他实施方案中,当式I聚合物的制剂可以喷洒在伤口部位上以便形成组织表面接触薄膜时,可以就地形成基材层。在各种不同的实施方案中,基材层可以预制成任何二维和三位形式的任何目的形状。一个或多个基材层可以垂直分层或堆叠,或以其它方式有利地组合、共混或混合以产生“多功能创伤护理敷料基质”(“MFWDM”)。
术语包含式I聚合物的“多功能创伤护理敷料基质”(“MFWDM”)旨在接触创伤部位的组织表面,以便提供能够促进受伤组织愈合并提供保护性物理屏障的多功能性质。在实施方案中,当式I聚合物的制剂可以喷洒在伤口部位上以便形成组织表面接触薄膜时,MFWDM可以就地形成。在各种不同的实施方案中,MFWDM可以预制成任何二维和三维形式的任何目的形状。MFWDM可以形成为本技术领域的专业人员已知的纺织织物层、无纺织物层、多孔薄膜、无孔薄膜、多孔膜、无孔膜、开孔泡沫、闭孔泡沫、纺织垫、无纺垫、网状物、衬垫、海绵、泡沫、纱布或等效物,和/或其组合。MFWDM可以生产成包含多层预制层,其中每个预制层发挥各种功能,包括:吸收过量流体,释放增湿剂,提供各种目标药剂,提供机械强度,防止水分丢失,促进胶原蛋白形成,促进组织再生。MFWDM可以通过任何手段固定在创伤部位处,包括用胶带粘、束紧和/或使用本技术领域的专业人员已知的任何粘合剂。MFWDM的实施方案包括的产品可以代替本技术领域的专业人员已知的其他类型创伤敷料、外科敷料、加压敷料、创可贴、加压绷带、伤口网织物、伤口盖布、伤口支架、外科织物粘合剂/胶带、医用级纱布、医用级衬垫、医用级海绵、烧伤敷料或等效物,和/或其组合。
术语“创伤”是指任何导致组织损伤、组织穿透、撕裂或损害的的受伤,包括由各种美容治疗引起的受伤。可接受MFWDM治疗的创伤包括可以位于任何部位包括内部、界面、外部、间隙、体外和/或体内的受伤。适合用本公开的MFWDM覆盖的创伤的实例包括:本技术领域的专业人员已知的割伤,砍伤,开放创伤,组织破裂,褥疮,皮炎,病变,慢性创伤,战场创伤,坏死性创伤,急性、慢性、外伤性伤口,擦伤,挫伤,坏死性筋膜炎,中毒性表皮坏死,压伤,静脉机能不全性溃疡,动脉性溃疡,糖尿病性或神经病理性溃疡,压迫性溃疡,混合型溃疡,烧伤,毛霉菌病,血管炎性创伤,坏疽性脓皮病(Pyoderma,gangrenosum),和等同者,和/或其组合。考虑到了使用本公开的MFWDM治疗人类和动物对象中的创伤。
术语“组织接触表面”是指目标多功能创伤护理基质打算与创伤部位进行接触的至少一个表面。
术语“基材层”是指构成MFWDM的各个层。但是,如果MFWDM包含两个或更多个层,那么与创伤部位直接接触的基材层具有组织接触表面,而其他基材层位于与创伤部位最接近的基材层的上方(“叠加的基材层”)。
术语“组织表面”包括人类和动物身体的内部、界面、间隙或外表面,例如但不限于血管、器官、皮肤、体腔、骨骼、软骨或其他等同物。
术语“掺入”是指式I的聚合物结构性整合到适合的目标MFWDM中,其中聚磷腈聚合物可以作为纤维、薄膜、膜、网、筛、垫或本技术领域的专业人员已知的等效物和/或其组合的成分掺入。
术语“包封”和“包层”和“掺合”可以互换使用,是指通过使用通式I的各种不同聚合物将基材层部分或完全地包围。MFWDM在聚磷腈基质的准确布置方面没有限制,例如聚磷腈基质可以用中间层包层(或成层)、与中间层反应、共混(或混合)、包埋、接枝、粘合、交联、共聚、用中间层包层和/或与其反应,所述中间层用其他常规的生物材料以任何方式包层和/或与其反应或组合。此外,聚磷腈可以与常规生物材料组合,所述组合可以包被在装置或表面上,使得聚磷腈和生物材料基本上在同时包层。任何材料包括或包含生物材料和聚磷腈的公开内容,或聚磷腈被添加到生物材料或医学装置中的公开内容,涵盖了所有这些情况。
术语“保护性屏障”是指下述的任何物理屏障:防止病毒、微生物、真菌感染,防止进一步身体损伤,防止从暴露的组织表面丧失流体,针对极端环境条件、包括极端热和冷的温度进行保护,针对环境中的水进入伤口进行保护,促进愈合,防止瘢痕形成,减少疼痛,减轻炎症,减少流血,促进血液凝结,防止与伤口表面粘连,促进胶原蛋白重新形成,促进组织再生,促进神经分布,促进血管生成,减少愈合时间和/或加快细胞生长速度。
术语“薄膜”是指可以通过本技术领域的专业人员已知的任何方法生产的,由任何材料、包括式I聚合物构成的任何二维基质。
术语“流体”或“液体”在指称接触性物质时可以互换使用,包括通常的液体、半固体、糊剂、溶胶或凝胶,例如可包含相当量可提取液体的药物软膏。
术语“泡沫”是指可以通过本技术领域的专业人员已知的任何方法生产的,由任何材料、包括式I聚合物构成的任何三维基质。
术语“喷雾器”是指任何加压气溶胶分配器,可用于散开式I聚合物的颗粒以便将聚合物就地沉积在靶创伤部位的顶部。
术语“载体单元(carrier member(s))”或“囊”可以互换使用,是指任何形状或表面轮廓的、主要由天然和/或合成聚合物构成的颗粒,其平均粒度在约10μm到约1200μm的范围内。载体单元可以包含任何目标分子,包括生长因子、肽、蛋白、激素、糖类、多糖、核酸、脂类、维生素、类固醇、抗生素、消炎药和有机或无机药物。
术语“去污剂”包括消毒剂例如ubck葡萄糖酸氯己定、甲基异噻唑酮、麝香草酚、α-松油醇、西吡氯铵、对氯间二甲苯酚或本技术领域的专业人员已知的等效物,和/或其组合。
术语“目标药剂”包括本技术领域的专业人员已知的各种不同类型的去污剂、愈合剂、渗出物吸收剂、抗微生物剂、抗病毒剂、抗真菌剂、抗瘢痕剂、抗组胺药剂、非甾类消炎药、抗血栓药剂、或等同物和/或其组合。
术语“愈合剂”包括一种或多种药物、生物活性剂、药用营养剂(nutraceutical)、或本技术领域的专业人员已知的等效物,和/或其组合。
术语“抗微生物剂”是指任何能够降低微生物水平的天然或合成的实体:青霉素;青霉素G,青霉素V,红霉素,林可霉素,克林霉素,新生霉素(novibiocin),万古霉素,梭链孢酸,利福平,多粘菌素,新霉素,卡那霉素,妥布拉霉素,庆大霉素,阿莫西林,氨苄青霉素,阿洛西林钠,双氯西林钠,福罗西林(furoxacillin),美西林,β-内酰胺酶抗性青霉素;甲氧西林,萘夫西林,苯唑西林,氯唑西林;新生霉素;白霉素,交沙霉素,麦里多霉素,麦迪霉素,螺旋霉素;林可霉素类,克林霉素,林可霉素;大环内酯类,蔷薇霉素;青霉素类,广谱青霉素;氨苄青霉素,阿莫西林,羧苄青霉素,替卡西林,哌拉西林,与青霉素联合给药的药物(β-内酰胺酶抑制剂);克拉维酸,舒巴坦,他唑巴坦;头孢菌素类抗生素;头孢噻吩,头孢唑啉,头孢氨苄,头孢拉定;头孢孟多;头孢克洛,头孢呋辛,头孢尼西,头孢西丁,头孢替坦,头孢噻肟,头孢他定,头孢哌酮,头孢唑肟,头孢曲松,头孢克肟,头孢吡肟,亚胺培南,美罗培南,单酰胺菌素,氨曲南,万古霉素,环丝氨酸,杆菌肽,磷霉素,氨基糖苷类;链霉素,新霉素,庆大霉素,妥布拉霉素,阿米卡星,奈替米星,布替罗星,双脱氧卡那霉素B(DKB),福帖霉素,庆大霉素,卡那霉素,里杜霉素,核糖霉素,沙加霉素类,昔尔杜霉素类及其差向异构体,西梭霉素,山梨菌素,妥布拉霉素;四环素类;四环素,土霉素,去甲金霉素,米诺环素,多西环素,大环内酯类;红霉素,克拉霉素,阿奇霉素,克林霉素,链阳菌素类,奎奴普丁-达福普汀,利奈唑胺,氯霉素,DNA合成抑制剂;磺胺类,磺胺嘧啶,乙酰磺胺,磺胺甲噁唑,磺胺多辛,柳氮磺吡啶,甲氧苄啶,氟喹诺酮类;环丙沙星,氧氟沙星,洛美沙星,诺氟沙星和依诺沙星。
术语“抗真菌剂”是指任何能够降低微真菌水平的天然或合成的实体,例如唑类(azoles),酮康唑、咪康唑、克霉唑、氟康唑、伊曲康唑,烯丙胺类,特比萘芬、萘替芬、两性霉素B、制霉菌素、氟胞嘧啶、灰黄霉素、奥昔康唑、联苯苄唑、布康唑、氯康唑、克霉唑、益康唑、恩康唑、芬替康唑、异康唑、咪康唑、硫康唑、噻康唑、氟康唑、伊曲康唑、特康唑、萘替芬和特比萘芬、吡啶硫酮锌以及羟吡酮(octopirox)。
术语“抗病毒剂”是指任何能够降低微生物水平的天然或合成的实体,例如三环胺类、金刚乙胺、金刚烷胺、神经氨酸苷酶抑制剂、奥司他韦、扎那米韦、核苷类似物、阿昔洛韦、伐昔洛韦、泛昔洛韦、潘昔洛韦、三氟胸苷、阿糖腺苷、更昔洛韦、缬更昔洛韦、西多福韦、焦膦酸盐、膦甲酸(forscarnet)、鸟苷类似物、病毒唑、糖蛋白类、α-干扰素和β-干扰素。
术语“局部麻醉剂”是指任何能够诱导麻醉、或可逆地抑制神经元功能、产生痛感的全部或部分丧失的天然或合成的实体,例如丁卡因、可卡因、普鲁卡因、奴佛卡因、苯佐卡因、丁哌卡因、麻卡因、罗哌卡因、耐乐品、依替卡因、益替多卡因、利多卡因、赛罗卡因、丙胺卡因(prilocaine)、丙胺卡因(citanest)、甲哌卡因、卡波卡因和异卡因。
术语“抗瘢痕剂”是指任何能够减少瘢痕形成的天然或合成实体,例如双嘧达莫、阿莫沙平、帕罗西汀、泼尼松龙、双嘧达莫、地塞米松、益康唑、双氟拉松、前列地尔、阿莫沙平、异丁司特、去甲替林、氯雷他定、阿苯达唑、戊双脒、伊曲康唑、洛伐他汀、特比萘芬和类固醇。
术语“抗组胺剂”包括能够降低组胺水平的天然或合成实体:抗组胺类(H1组胺拮抗剂)例如溴苯那敏、氯苯那敏、右氯苯那敏、曲普利定、氯马斯汀、苯海拉明、双苯拉林、曲吡那敏、羟嗪、甲地嗪、异丙嗪、异丁嗪、阿扎他定、二苯环庚啶、安他唑啉、非尼拉敏、吡拉明、阿司咪唑、特非那定、氯雷他定、西替立嗪、非索非那定、去羧乙氧基氯雷他定等。
术语“非甾类抗炎剂(NSAID)”是指任何能够减轻炎症的天然或合成实体,例如丙酸衍生物(例如氨洛芬、苯噁洛芬、布氯酸、卡洛芬、芬布芬、非诺洛芬、氟洛芬、氟比洛芬、布洛芬、吲哚洛芬、酮洛芬、咪洛芬、萘普生、奥沙普秦、吡洛芬、普拉洛芬、舒洛芬、噻洛芬酸和硫噁洛芬),乙酸衍生物(例如吲哚美辛、阿西美辛、阿氯芬酸、环氯茚酸、双氯芬酸、芬氯酸、芬克洛酸、芬替酸、呋罗芬酸、异丁芬酸、伊索克酸、oxpinac、舒林酸、硫平酸、托美丁、齐多美辛和佐美酸),芬那酸衍生物(例如氟芬那酸、甲氯芬那酸、甲芬那酸、尼氟酸和托芬那酸),联苯基甲酸衍生物(例如二氟尼柳和氟苯柳),昔康类(例如伊索昔康、吡罗昔康、舒多昔康和替诺昔康),水杨酸(例如乙酰水杨酸和柳氮磺吡啶),以及吡唑酮类(例如阿扎丙宗、bezpiperylon、非普拉宗、莫非布宗、羟布宗和保泰松)和环加氧酶-2(COX-2)抑制剂例如塞来昔布(CelebrexTM)和罗非昔布(VioxxTM)。
术语“阿片样镇痛剂”包括可待因、芬太尼、氢吗啡酮、左啡诺、哌替啶、美沙酮、吗啡、羟考酮、氧吗啡酮、丙氧芬、丁丙诺啡、布托啡诺、地佐辛、纳布啡、戊唑辛、芬太尼(Fentanyl)、芬太尼(Sublimaze)、舒芬太尼、苏芬他、阿芬太尼、阿芬他、瑞芬太尼、瑞芬太尼粉针剂(Ultiva)、哌替啶、德美罗、美沙酮、多罗芬、吗啡、氢吗啡酮、盐酸氢吗啡酮(Dilaudid)、氧吗啡酮、盐酸羟氢吗啡酮、可待因与对乙酰氨基酚、阿司匹林、羟考酮与对乙酰氨基酚、Percocet、复方羟可酮、二氢可待因、氢可酮与对乙酰氨基酚、维柯丁与布洛芬、丙氧芬左啡诺、左吗南、布托啡诺、酒石酸布托啡诺制剂(Stadol)、丁丙诺啡、布诺啡、纳布啡、纳布啡注射剂(Nubain)、戊唑辛、镇痛新、地佐辛、地佐辛制剂(Dalgan)、纳络酮、烯丙羟吗啡酮(Narcan)、纳曲酮、Re Via、纳曲酮制剂(Depade)、纳美芬、Revex、苯乙哌啶、洛哌丁胺、易蒙停和右美沙芬,以及合成或天然的内啡肽作用物质。
术语抗血栓形成剂包括溶栓剂,链激酶、阿替普酶、阿尼普酶、瑞替普酶、肝素、水蛭素、华法林衍生物、β-阻断剂、阿替洛尔、β-肾上腺素能激动剂、异丙基肾上腺素、ACE抑制剂、血管舒张剂、硝普钠、盐酸尼卡地平、硝酸甘油和依那普利拉。
术语“渗出物吸收剂”是指任何能够吸收从受伤组织部位排出的过量流体的物质,可以生产成任何形式或形状,例如平片、珠子、糊剂、粉末、薄片或等同物,和/或其组合。
B.掺有式I的聚磷腈的多功能创伤护理敷料基质
1、所考虑的多功能创伤护理敷料基质的概述
在各种不同实施方案中,本公开的多功能创伤护理敷料基质(“MFWDM”)能够在创伤部位处保护并促进新组织的生长。所考虑的MFWDM通过将受伤组织保护在营养环境中并先行提供其他组织再生促进因子以促进给定创伤部位处的愈合速度,表现出能够对创伤护理进行管理的性质。如果需要,式I聚磷腈的先进的性质能够延长对各种生物流体和脆弱组织的暴露时间。
图1是作为本公开的一个实施方案,能够掺入到多功能创伤护理基质中的一片设想的基材层的示意图。在图1中,显示了一片示例性基材层100,代表了用于构建多功能创伤护理敷料基质的基础层。适合用于生产基材层100的材料包括任何合成聚合物、聚合物共混物,以及源自于植物、矿物或动物来源的天然存在的有机或无机材料。目标基材层100的片可以切割成大量形状中的任一种,正方形、圆形、椭圆形、半月形、矩形等。基材层的适合厚度可以在从约10μm直至约1cm、从约10μm直至约80mm、从约10μm直至约60mm、从约10μm直至约50mm、从约10μm直至约40mm、从约10μm直至约30mm、从约10μm直至约20mm、从约10μm直至约10mm、从约10μm直至约5mm以及从约10μm直至约1mm的范围内。一个或多个设想的基材层可以垂直组装、或堆叠,以产生目标多功能创伤护理敷料基质。MFWDM可以放置在创伤部位110上,以便在愈合过程中提供保护性物理屏障。当放置在创伤部位110上时,MFWDM的组织接触表面120与体液例如血液或渗出物和/或细胞性组织物质进行直接或间接接触。
许多保护性屏障材料,例如无菌创伤敷料、排液材料、衬垫、贴片、创可贴、纱布、泡沫、海绵等,可以由改性的天然产物与合成聚合物的组合来制造或衍生,因为如此产生的复合材料表现出多种优点,包括物理和机械弹性性质和/或在产生所需形状方面的制造和加工控制。可以作为适合的基材层掺入、用于生产多功能创伤护理敷料基质的合成或天然聚合生物材料的实例包括但不限于聚氨基甲酸酯、聚碳酸酯、聚酯、聚酰胺、聚酰亚胺、聚乙烯、聚烯烃、特氟龙TM、Gore-TexTM、聚乙烯醇、聚氧化乙烯、聚丙烯酸酯、聚甲基丙烯酸酯和聚氰基丙烯酸酯、乳胶、聚氯乙烯、聚乳酸和聚乙醇酸衍生物、水凝胶形成剂例如PHEMA、聚环氧乙烷、透明质酸、脱乙酰壳多糖、藻酸盐、纤维素和本技术领域的专业人员已知的其他等效物。组成目标基材层的每种天然或合成纤维可以形成为独立纺成的纤维、作为纤维束、作为绞合线、作为纺织物、作为无纺织物、作为编织物、作为结织物或任何等同物,及其任何组合。
在各种不同的实施方案中,适用于生产多功能创伤护理敷料基质的基材层包含至少一种通式(I)的聚合物。在各种不同的实施方案中,适用于生产多功能创伤护理敷料基质的基材层包含聚[双(三氟乙氧基)聚磷腈]和/或其衍生物。
在各种不同的实施方案中,多功能创伤护理敷料基质可以掺入式I的聚磷腈(在下文定义),作为能够构造成各种形式的成分,包括作为具纤维/非纤维垫、多孔/无孔膜、多孔/无孔薄膜、开孔/闭孔泡沫、用于喷涂施加的颗粒制剂、这些形式的等同物及其组合。
在各种不同的实施方案中,通过掺入式I的聚磷腈作为成分,例如作为主要结构性成分、作为包封另一种结构性成分的包层、和/或作为支持各种非结构性功能的介导成分,多功能创伤护理敷料基质能够表现出聚磷腈固有的杰出性质。
在各种不同的实施方案中,多功能创伤护理敷料基质可以掺入式I的聚磷腈作为MFWDM的结构性成分,例如100,其中结构性成分的一个表面可以起到组织接触表面的作用。
在各种不同的实施方案中,多功能创伤护理敷料基质可以掺入式I的聚磷腈作为MFWDM的结构性成分例如100的包层,其中包封结构性成分的包层至少可以起到组织接触表面的作用。
在各种不同的实施方案中,多功能创伤护理敷料基质可以掺入式I的聚磷腈作为介导成分,其中介导成分能够起到提供大量功能的作用,所述功能包括作为载体单元,能够储存各种不同的目标药剂,例如本技术领域的专业人员已知的生物活性剂、药物组合物、药用营养剂,以及促进组织愈合和组织再生的其他等效物。在各种不同的实施方案中,式I的MFWDM可以起到居间的MFWDM界面或装置表面成分的外表面的作用。
2、多功能创伤护理敷料基质的优点和高性能性质
在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质,与常规用作生物材料的其他聚合材料相比时,能够表现出优越的生物和血液相容性性质。掺入式I的聚磷腈作为本公开的目标MFWDM的成分,能够显著降低致血栓性和血小板粘附,因此能够特别好地适合作为所考虑的各种MFWDM的血液接触和/或软组织接触成分。
在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质能够表现出抗炎性质。掺入式I的聚磷腈作为本公开的目标MFWDM的成分,能够显著减少给定创伤部位的炎症。在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质能够表现出抗细菌性质。掺入式I的聚磷腈作为本公开的目标MFWDM的成分,能够显著减少细菌与MFWDM的附着,从而促进无菌环境的维持。在各种不同的实施方案中,由于防止了细菌浸润,本公开的掺有式I聚合物的MFWDM能够表现出气味吸收性质。
在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质能够表现出润滑、或非粘性、非粘连和拒液性质。掺入式I的聚磷腈作为本公开的目标MFWDM的成分,能够显著降低MFWDM的组织接触表面与给定创伤部位的脆弱表皮层之间的粘连程度。将MFWDM从生物基底例如人类和动物对象的各种细胞组织的表面剥离而不引起对生物基底的附加组织伤害,通过减少在移除过程中引入的继发性并发症,例如未愈合创伤的过早重新打开、破坏周围组织的完整性、或增加引入病原性感染的风险,而提供了显著优点。因此,式I的聚磷腈的非粘性、拒水分的性质能够促进组织愈合,并能够以最小的不适和疼痛移除MFWDM。
在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质能够表现出拒流体、流体附着(润湿)或流体运输性质,后一种性质不完全是MFWDM材料的表面能和密度的功能。因此,掺入式I的聚磷腈作为本公开的目标MFWDM的成分,能够起到在装置与流体接触时稳定装置的所需界面性质或促进流体穿过保护性屏障运输的作用。在上述MFWDM材料的一个实施方案中,拒流体性质可以起到将液体基本上维持在高于与创伤接触的保护性屏障材料的上方、或材料表面向创伤的表面的下方的作用。因此,这种效应可以辅助地帮助将例如接触传染性、感染性或脓毒性流体包含在保护性屏障材料的表面(面向创伤)的下方,增加与(受伤)人员直接接触的工作人员的医疗安全性。该实施方案的另一个可能需要的效应是将创伤与透过保护性载体材料的液体或水分遮蔽开,这也将帮助维持装置的耐用性、创伤的(粘附性)和所需的环境/湿度状态。此外,它可以防止臭味(例如从创伤部位处的有机物质、细菌、坏死组织的分解而产生的)发散到外部环境,为患者和健康护理人员增加了进一步的舒适。在上述MFWDM材料的另一个实施方案中,液体润湿作为特点,能够帮助维持创伤中一定程度的液体饱和,或主动促进液体(例如包含药剂的)运输到创伤中,例如用于创伤保湿(例如在按计划移除保护性屏障之前)或易于医学处理。拒流体性或粘附性质的平衡本身可以表现为流体运输能力。
在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质,通过在较长时期内不与生理流体的成分发生反应,能够表现出杰出的生物稳定性性质。掺入式I的聚磷腈作为本公开的MFWDM的成分,可以赋予超常的生物惰性以提供被动屏障,所述被动屏障能够起到有效的保护性物理屏障以及水分屏障的作用。在各种不同的实施方案中,本公开的掺有式I的聚磷腈作为成分的多功能创伤护理敷料基质,通过在较长时期内不与生理流体成分进行反应,可以表现出杰出的生物稳定性性质。掺入式I的聚磷腈作为本公开的MFWDM的成分,可以赋予超常的生物惰性以提供被动屏障,所述被动屏障起到有效的保护性屏障的作用。作为在生理或其他流体中稳定性的次要好处,MFWDH能够起到位于例如液体或凝胶基软膏或储池之间的中间层的作用,用于将附加的药剂从储池运输到创伤环境。
3、式I的聚合物的定义
在各种不同的实施方案中,本公开的多功能创伤护理敷料基质包含通式(I)的聚合物。各种不同的实施方案涉及含有聚合化合物聚[双(三氟乙氧基)聚磷腈]和/或其衍生物的多功能创伤护理敷料基质。
各种不同的实施方案涉及包含基材层的多功能创伤护理敷料基质(“MFWDM”),所述基材层形成为包含至少一个组织接触表面的创伤敷料基质,其掺有至少一种具有通式(I)的聚合物成分:
其中n值是从2到∞的整数;
R1到R6独立地选自:
取代或未取代的烷基、烷氧基、芳基、芳氧基、甲硅烷基、甲硅烷氧基、烷基磺酰基、烷基氨基、二烷基氨基、脲基、羧酸酯、烷基单脒、烷基双脒、烷氧基单脒或烷氧基双脒;或氨基;
具有至少一个氮、磷、氧、硫或硒作为杂原子的杂环烷基;
具有至少一个氮、磷、氧、硫或硒作为杂原子的杂芳基;
核苷酸或核苷酸残基;
生物大分子;或
嘧啶或嘌呤碱基。
R1至R6的适合的取代基可以独立地选自:卤化物取代基例如氟、氯、溴或碘,拟卤化物取代基例如氰基(-CN)、异氰基(-NC)、氰硫基(-SCN)、异氰硫基(-NCS)、氰酰基(-OCN)、异氰酰基(-NCO)、叠氮基(-N3),取代基例如硝基(-NO2)和亚硝基(-NO),部分取代的烷基例如卤代烷基,杂芳基例如咪唑基、噁唑基、噻唑基、吡唑基的衍生物,或嘌呤和嘧啶碱基例如胍、脒和碱基结构的其他脲基衍生物。
本文中使用的烷基(R)、烷氧基(-OR)、烷基磺酰基(-SO2R)、烷基氨基(-NHR)、二烷基氨基(-NR2)、羧酸酯(-(链二烷基)C(O)OR或-(链二烷基)OC(O)R))、脲基(-NHC(O)NH2、-NRC(O)NH2、-NHC(O)NHR、-NRC(O)NHR、-NHC(O)NR2、-NRC(O)NR2、及其链二烷基连接的类似物)、烷基单脒(包括-N=C(NR2)R、-(链二烷基)N=C-(NR2)R、-C(NR2)=NR和-(链二烷基)C(NR2)=NR)、烷基双脒(包括-N=C(NR2)2、-(链二烷基)N=C(NR2)2、-NRC(NR2)=NR和(链二烷基)NRC(NR2)=NR)、烷氧基单脒(-O(链二烷基)N=C(NR2)R、-OC(NR2)=NR和-O(链二烷基)C(NR2)=NR))和烷氧基双脒(-O(链二烷基)N=C(NR2)2、-O(链二烷基)NRC(NR2)=NR和O(链二烷基)NRC(NR2)=NR)部分由所显示的相应式定义,其中R可以独立地选自直链、支链和/或环状(“环烷基”)烃基部分,包括具有1到20个(例如1到12个、或1到6个)碳原子的烷基(饱和烃类)以及烯基和炔基部分。
包含烯基和炔基部分特别提供了将聚磷腈部分交联到任何所需程度的能力。烷基的实例包括但不限于甲基、乙基、丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、戊基、异戊基、新戊基、己基、异己基、庚基、4,4-二甲基戊基、辛基、2,2,4-三甲基戊基、壬基、癸基、十一烷基和十二烷基。环烷基部分可以是单环或多环的,其实例包括环丙基、环丁基、环戊基、环己基和金刚烷基。烷基部分的其他实例具有直链、支链和/或环状部分(例如1-乙基-4-甲基-环己基)。
根据这种定义和用法(如上),R(烷基)基团的具体实例包括未取代的烷基、取代的烷基例如卤素取代的烷基(卤代烷基)、未取代的烯基、取代的烯基例如卤素取代的烯基,以及未取代的炔基和取代的炔基例如卤素取代的炔基。
此外,这些R(烷基)的实例提供了烷氧基(OR)取代基可以是未取代的烷氧基(“烷基氧基”)、取代的烷氧基例如卤素取代的烷氧基(卤代烷氧基)、未取代的烯氧基、取代的烯氧基例如卤素取代的烯氧基、未取代的炔氧基和取代的炔氧基例如卤素取代的炔氧基。在这方面,乙烯氧基和烯丙氧基可能是有用的。
甲硅烷基是-SiR3基团,甲硅烷氧基是-OSiR3基团,其中每个R部分独立地选自如上定义的R基团。也就是说,在每种情况中,R独立地选自直链、支链和/或环状(“环烷基”)烃基部分,包括具有1到20个(例如1到12个、或1到6个)碳原子的烷基(饱和烃类)以及烯基和炔基部分。
除非另有指明,否则任何R基团可以是未取代或独立地被至少一个取代基取代的,所述取代基选自卤素(氟、氯、溴或碘)、烷基、烷基磺酰基、氨基、烷基氨基、二烷基氨基、脒基(-N=C(NH2)2)、烷氧化物或芳基氧化物,如果适用,它们任一个均可以具有多达6个碳原子。因此,术语取代的“烷基”和包含取代的烷基例如“烷氧基”的部分,分别包括卤代烷基和卤代烷氧基,包括任何氟、氯、溴和碘取代的烷基和烷氧基。因此,术语卤代烷基和卤代烷氧基是指用一个或多个卤素原子即氟、氯、溴或碘包括其任何组合取代的烷基和烷氧基。
除非另有指明,否则术语“芳基”是指由碳和氢原子构成的芳香环或者芳香族或部分芳香族环系统,其可以是单环部分,或可以包含多个连接或稠合在一起的多个环。芳基部分的实例包括但不限于苯基、蒽基、甘菊环基、联苯基、芴基、茚满、茚基、萘基、菲基、1,2,3,4-四氢萘、甲苯基等,其任一个具有最多20个碳原子。芳氧基是指-O(芳基)部分。
术语卤代芳基和卤代芳氧基分别是指被一个或多个卤素原子即氟、氯、溴或碘包括其任何组合取代的芳基和芳氧基。
具有至少一个氮作为杂原子的杂环烷基是指非芳香族杂环,包括其中环结构中的一个或多个原子是氮而不是碳的环烷基或环烯基部分,其可以是单环或多环,并且可以包括外型羰基(exo-carbonyl)部分等。含有氮作为杂原子的杂环烷基的实例包括但不限于哌嗪基、哌啶基、吡咯烷基、四氢嘧啶基、吗啉基、吖丙啶基、咪唑烷基、1-吡咯啉、2-吡咯啉或3-吡咯啉、吡咯烷酮基、哌嗪酮基、乙内酰脲基、哌啶-2-酮,吡咯烷-2-酮、吖丁啶-2-酮等。因此,这些基团也包括杂环的环外酮。
具有至少一个氮作为杂原子的杂芳基是指其中环结构中一个或多个原子是氮而不是碳的芳基部分,其可以是单环或多环的。具有氮作为杂原子的杂环烷基的实例包括但不限于吖啶基、苯并咪唑基、喹唑啉基、苯并喹唑啉基、咪唑基、吲哚基、异噻唑基、异噁唑基、噁唑基或噁二唑基、酞嗪基、吡嗪基、吡唑基、哒嗪基、吡啶基、嘧啶基(pyrimidinyl)、嘧啶基(pyrimidyl)、吡咯基、喹唑啉基、喹啉基、四唑基、噻唑基、三嗪基等。在这方面,本公开包括或涵盖了在广范围的药剂、天然部分、天然生物分子和生物大分子中作为亚基发现的化学部分。例如,本公开涵盖了许多现有的药剂,它们具有四唑基团(例如氯沙坦、坎地沙坦、厄贝沙坦和其它血管紧张素受体拮抗剂)、三唑基团(例如氟康唑、艾沙康唑、伊曲康唑、伏立康唑、普拉康唑、泊沙康唑和其他抗真菌剂)、二唑类(例如杀真菌剂例如咪康唑、酮康唑、克霉唑、益康唑、联苯苄唑、布康唑、芬替康唑、异康唑、奥昔康唑、舍他康唑、硫康唑、噻康唑等),以及咪唑类(组氨酸、组胺等)。因此,在一个方面,式I中的某些R1到R6部分可以涵盖在广范围的药剂、天然部分、天然生物分子和生物大分子中作为亚基发现的化学部分。
具有至少一个磷、氧、硫或硒作为杂原子的杂环烷基是指非芳香族杂环,包括环结构中一个或多个原子是磷、氧、硫或硒而不是碳的环烷基或环烯基部分,其可以是单环或多环的,并且可以包括外型羰基部分等。同样地,具有至少一个磷、氧、硫或硒作为杂原子的杂芳基是指环结构中一个或多个原子是磷、氧、硫或硒而不是碳的芳基部分,其可以是单环或多环的。具有磷、氧、硫或硒作为杂原子的杂环烷基或杂芳基的实例包括但不限于取代或未取代的氧化乙烯(环氧化物、环氧乙烷)、环氧乙烯、环氧丙烷、四氢呋喃(氧杂环戊烷)、二氢呋喃、呋喃、吡喃、四氢吡喃、二噁烷、二噁英、硫杂环丙烷(环硫化物)、硫杂环丁烷、四氢噻吩(噻戊烷)、二氢噻吩、噻吩、噻烷、thiine(噻喃)、噁嗪、噻嗪、二噻烷、二硫杂环丁烷等。因此,这些基团包括所有异构体,包括所引述化合物的区域异构体。例如,这些基团包括1,2-和1,3-噁唑、噻唑、硒唑、磷唑等,它们包含了来自15族或16族元素的不同杂原子。
4、用于在目标基材上形成稳定的式I聚合物包层的示例性方法
作为示例性方法,可以通过在目标基材与含有式I聚合物的包层之间的界面处引入化学修饰,在基材表面与包层之间形成稳定的键合。可以通过在目标聚合物基材表面与式I聚合物之间诱导共聚物例如随机共聚物、交替共聚物、嵌段共聚物、接枝共聚物、共混物或互穿网络的形成,引入适合的界面。
例如,“A”表示式I聚合物的骨架,“B”表示基材表面的聚合物的骨架。下面的图解将帮助理解这一概念:
在该图示中省略了侧基。
“A”和“B”的无规共聚物
“A”和“B”的嵌段共聚物
除了该图示中描述的连接性之外,连接性不仅可以通过将骨架与骨架单元按照所描绘的相连而获得,而且它还可以包括将一种聚合物的一个或多个侧基与另一种聚合物的一个或多个骨架单元相连,或一种聚合物的一个或多个侧基与另一种聚合物的一个或多个侧基的连接,及其所有可能的排列。此外,这些连接性不限于两种聚合物形成共聚物,而是还可以包括第三种或更多的聚合物,或参与骨架或侧基单元之间的键形成的适合的连接部分。因此,该定义还包含了由乙烯亚胺或氨基硅烷等如同包层所述而构成的连结层(tie layer)。
聚合物的共混物可以描述成聚合物“A”在“B ”中的任何任意混合物,通常通过使用每种聚合物的适合的共溶剂或使用熔体来形成。形成均质或逐渐融合的共混物比形成具有一个以上相的非均质共混物更加优选。
互穿网络可以理解成聚合物链(带有侧基的骨架单元)从一种聚合物扩散到另一种聚合物中,并与另一种的聚合物链相互作用,以在不同聚合物之间产生适合的粘附。在本发明的情况中,术语半互穿网络是优选的,因为一种聚合物(基础基材(base substrate))可以由交联的聚合物链构成,而另一种(顶部(top-))聚合物(式I聚合物)可以是非交联的并正扩散到另一种聚合物中。半互穿网络与互穿网络的差别在于一种或多种聚合物是交联的并形成稳定的网络基质,而另一种聚合物是非交联的。在真正的互穿网络中,两种聚合物都可以是交联的。共聚物形成技术提供如下:
有几种策略能够有效导致任何上述共聚物的形成。共聚物可以通过同时将两种聚合物的前体(单体单元或非常小的低分子量分子单元)的适当混合物“共同”聚合来形成。取决于使用的条件(同时或逐步反应,自组织/装配反应......),这可以为形成两种或更多种聚合物全在一起的随机、交替、嵌段共聚物、共混物或(半)互穿网络提供实例。
“A”接枝到“B”上
通过将一种聚合物的这些单体/前体单元附着到另一种聚合物上,然后在“接枝”到另一种聚合物的骨架上的同时使这些单体单元聚合,能够形成稳定的共聚物。在本文情况下,这可能意味着将适合的磷腈前体与来自基础基材的适合前体或聚合物链进行共聚。这是将“A”接枝到“B”上的方法的实例,其中式I聚合物(和/或其前体)的链被接枝到基础基材聚合物的骨架上。这种类型的接枝方法也可以包括相对于纯的基础基材聚合物相与纯的式I聚合物相之间的距离,逐步增加式I聚合物的接枝侧链的分子量。分子量的逐渐变化将增加式I聚合物向基础基材聚合物相中的扩散,同时允许表面能的逐渐跃迁,降低相分离或粘附失效的风险。式I聚合物的适合前体构成如下:
在开环聚合期间使用的环状磷腈前体
侧基R-可以包含卤素元素,例如氟、氯、溴和碘原子。在这种情况下,最优选使用的是氯,对此存在已知的现有技术。此外,基团R-可以包含主族VII元素的任何已知类似物,即等瓣(等电子)片段。示例性的等瓣片段可以包括但不限于氰基、硫代氰酸酯基、氰酸酯基和叠氮基。其他常用有机侧基例如-COOH、-NH2也可以用作适合的侧基,只要电负性取代基特性允许等离子体反应性与对含氯取代基所证明的相似即可。在最优选的实施方案中,侧基R-由醚部分-OR构成,例如-OEt、-OMet,但最优选的是-OCH2CF(3-m),其中m=0-2。此外,适合的磷腈前体不仅可以是环状的,而且可以包括直链的低分子量式I聚合物或式I聚合物的交联链。这种类型的接枝也可以通过使用在聚合物的末端位置中含有基础基材锚定基团的式I聚合物来实现。
“B ”接枝到“A”上
在另一种情况下,可以通过用适合的反应性短链侧基将反应性基础基材基团接枝到式I聚合物骨架上,来形成共聚物。共聚物形成中的其他策略包括通过适合的试剂连接侧基。
互穿网络(IPN)
互穿网络的成功形成主要取决于两种聚合物通过适合的共溶剂介导,产生稳定的均质混合物,所述共溶剂对一种聚合物具有恰当的溶解度程度,同时对另一种聚合物维持足够的溶解度,所以两种聚合物相不分离。稳定的互穿网络的形成可以包括根据纯的基础基材聚合物相与纯的高分子量式I聚合物相之间的距离,以增加沉积的式I聚合物的分子量而逐步沉积式I聚合物的层。分子量的逐渐变化将增加式I聚合物扩散到基础基材聚合物相中,同时允许表面能的逐渐跃迁,降低不想要的相分离或粘附失效的风险。此外,第一层式I聚合物与基础基材的最初键合可以包括如前所述沉积适合的前体,使用随后的热、辐射诱导的或等离子体诱导的聚合、交联反应,使前面描述的式I聚合物或其前体在基础基质域内互相扩散。对于任何上面描述的混合物来说,重要的是在聚合混合物的固化阶段期间可能是需要相分离。因为形成最终部分的基础聚合物基材的单体部分将在固化过程中被耗尽,由于式I聚合物的主要疏水的本性,将存在着混合物的疏水部分在固化过程中向胶束结构外部定位或集中的趋势(由于表面能)。
C.掺有式I聚合物的示例性多功能创伤护理敷料
如上所述,包含式I聚合物和各种目标聚合物网络的多功能创伤护理敷料基质(“MFWDM”)可以被制造成具有开孔或闭孔或半闭孔设计。这些结构的孔隙度可以进一步是纳孔、中孔、微孔或大孔的。结构还可以由孔格状、纤维状、纤丝状、孔状或毛细管状、或圆柱状或管状单元(elements)构成,它们都可以排列成各向同性、各向异性或各自对称的不对称方式,或可以根据单元的尺寸逐渐降低或增加、或其结构而包含梯度。
或者,包含式I聚合物的多功能创伤护理敷料基质MFWDM可以产生成封闭的、部分封闭的或开放的、多孔或半多孔的、光滑或粗糙的、或特别构造或结构化的薄膜或层。这些薄膜或层及其相应的结构单元可以产生成在纳米直至微米到毫米的范围内的尺寸。作为逻辑上的扩大,这种结构和尺寸参数的重复、组合或倍增允许将本发明的尺寸范围扩展到更大的尺度。
图2是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质的示意图。在图2中,MFWDM 200包含两层并置在一起的基材层210和220。式I的聚合物可以掺入到任一或两个膜210和220中。两层基材层可以用任何方式并置,包括粘合、掺合、浸涂、喷涂、——。基材层适合作为本技术领域的专业人员已知的任何尺寸或形状的薄膜、膜、网状物、箔、纱布、衬垫、泡沫、海绵或等效物。当位于创伤部位230上方时,MFWDM的组织接触表面240与体液例如血液或渗出物和/或细胞组织物质进行直接或间接接触。构成MFWDM的基材层的层数可以在约2到约30、约2到25、约2到20、约2到15、约2到10和约2到5的范围内。图1中基材层的描述适用于图2-4中描述的实施方案。
图3是作为本公开的一个实施方案,包含多个层的多功能创伤护理敷料基质的示意图,并包含囊。在图3中,MFWDM 300包含两层以任何方式并置在一起的基材层310和320。MFWDM 300还包含含有一种或多种目标药剂的囊例如330和340,它们可以代表目标药剂的混合物,所述药剂选自本技术领域的专业人员已知的、能够促进愈合并刺激新组织生长的多种药物、生物活性剂或天然或合成的其他目标化合物或组合物。囊可以由天然或合成的可生物降解的聚合物或其共混物构成。当位于创伤部位350上方时,MFWDM的组织接触表面360与体液例如血液或渗出液、和/或细胞组织物质进行直接或间接接触。构成MFWDM的基材层的层数可以在约2到约30、约2到25、约2到20、约2到15、约2到10和约2到5的范围内。
图4是作为本公开的一个实施方案,包含多个基材层、并包含制成泡沫/海绵的式I聚合物的多功能创伤护理敷料基质的示意图。在图4中,MFWDM 400包含至少三层基材层:可渗透或不可渗透的聚磷腈层410,它上面是适用于液体摄取的水凝胶储层420,储层420上面是可渗透聚磷腈层430,其中所述基材层可以用任何方式并置在一起,并可以通过电旋涂、喷涂或本技术领域的专业人员已知的其他已建立方法来产生。可渗透聚磷腈层430可以生产成表现出多孔、纤维状或毛细管亚结构,包括例如泡沫、海绵、薄膜、纺织或无纺膜或本技术领域的专业人员已知的等同物的形式。当位于创伤部位440上方时,MFWDM的组织接触表面450与体液例如血液或渗出液和/或细胞组织物质进行直接或间接接触。构成MFWDM的基材层的层数可以在约2到约30、约2到25、约2到20、约2到15、约2到10和约2到5的范围内。
图5是作为本公开的一个实施方案,包含多个基材层的多功能创伤护理敷料基质、并制成为粘合性创伤贴片的示意图。在图5中,MFWDM 600包含至少四层基材层:聚磷腈来源的顶层510,它上面是液体吸收剂水凝胶层(作为例如泡沫/海绵)520,凝胶层上面是可渗透的聚磷腈层530,再上面是粘合剂层540,其中基材层可以用任何方式并置在一起,并可以通过电旋涂、喷涂或本技术领域的专业人员已知的其他已建立方法来产生。水凝胶层520可以由carylate、透明质酸盐、藻酸盐、脱乙酰壳多糖、聚环氧乙烷或PHEMA聚合物衍生物构成。粘合剂层540可以由可生物降解的聚合物、或氰基丙烯酸酯、或醋酸纤维素或聚氨基甲酸酯构成,并可以制造成通过光、热或水分激活。当位于创伤部位550上方时,MFWDM的组织接触表面560与体液例如血液或渗出液和/或细胞组织物质进行直接或间接接触。构成MFWDM的基材层的层数可以在约2到约30、约2到25、约2到20、约2到15、约2到10和约2到5的范围内。
在各种不同的实施方案、包括在图1-5中描述的实施方案中,掺有式I聚合物的MFDWM还包含管式部件,它可以采取当MFDWM的组织接触表面位于创伤部位上方时允许排除体液的方式附着于MFDWM。在各种不同的实施方案中,包含组织接触表面的基材层是一种或多种泡沫/海绵,所述泡沫/海绵能够与其他非常具有吸附性、多孔和耐用的材料融合在一起。当使用外部源施加负压(真空)时,过量的渗出液至少可以通过包含式I聚磷腈的组织接触层的毛细管结构从创伤部位排除,所述外部源可以是手动操作的或自动化的真空产生泵或其等效物。
本公开涉及制备和应用具有任意形状和形式的三维本体(体积)材料和/或二维膜片形式的定制聚磷腈基质(例如薄膜、纤维、膜、板片、海绵、泡沫、衬垫和球形、圆柱形、层状组合物)、复合材料或纯材料(整体增加或构成装置的底层结构或由几种成分构成)的技术,通过能够控制特定的聚磷腈基质的性质例如孔隙度、渗透性、扩散性、结构和尺寸范围(例如薄膜厚度和横向尺寸)、弹性模量、折射率、表面能、内聚能密度以及表面或本体形态,所述基质和材料传递了针对目标应用、装置的所需功能或装置本身改进的有益性质。此外,在创伤护理医学中聚磷腈基质定向用于拓扑器械,其目的是用作保护性屏障材料或其他所需的功能。
聚磷腈基质材料的上述物理性质,可以在用作生物材料时显示为生物医学特性行使直接影响。生物材料的某些上述性质包括例如细胞和细菌附着或其增殖、有机或无机结壳和物质积累的趋势、激活血液凝结级联、血栓形成的风险或补体系统的激活及其对生物接受性的影响、和医学装置与宿主对象的协调性。用作保护性屏障材料的装置的其他重要性质包括气体和液体通透、运输或扩散,例如空气和水性流体、血液、血清、细胞间和细胞内流体、药剂,对细菌浸润的抗性,以及针对环境条件例如湿度、温度条件(热/冷)、机械冲击、摩擦等的总体保护能力。
控制聚磷腈基质材料的物理性质的能力,构成了开发医学保护性屏障/创伤护理装置和(由此使)聚磷腈基质材料(可用于)有用于医学装置和应用的主要改进。因此,该技术应用的所需领域和应用的主要重点和范围集中于现代医学移植技术和智能生物材料的运用。这并不意味着限制本发明技术的范围或其可能的应用,并将进一步给出具体的实施例。
增塑剂、润滑剂、粘合剂、一般的聚合物添加剂以及聚合物分解产物,可以表面迁移并随着时间从装置滤出,从而不仅引起机械弹性性质的有害变化,而且影响生物学性质并可能随着使用时间的过程而引起对保护性屏障装置的不利的生物学响应,从而逐渐降低或破坏装置的生物相容性。在下面提供的实施例制剂中使用的溶液,可以与其他聚合剂、粘合剂、粘附促进剂、发泡剂、填充剂、药剂混合,以便提供相应共混的膜材料。
各种不同的实施方案涉及了用于生产多功能创伤护理敷料基质的方法,所述方法包括:
在形成为创伤敷料的基材层的至少一个组织接触表面上,掺入至少一种式(I)的高分子量聚磷腈聚合物:
其中
n是从约40到约100,000的整数;
R1到R6独立地选自:
a)取代或未取代的烷基、烷氧基、芳基、芳氧基、甲硅烷基、甲硅烷氧基、烷基磺酰基、烷基氨基、二烷基氨基、脲基、羧酸酯、烷基单脒、烷基双脒、烷氧基单脒或烷氧基双脒;或氨基;
b)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂环烷基;
c)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂芳基;
d)核苷酸或核苷酸残基;
e)生物大分子;或
f)嘧啶或嘌呤碱基。
各种不同的实施方案涉及了用于创伤愈合的方法,所述方法包括:
用多功能创伤护理敷料基质覆盖创伤部位,所述敷料基质包含:
基材层,所述基材层形成为包含至少一个组织接触表面的创伤敷料并掺有至少一种式(I)的高分子量聚磷腈聚合物:
其中
n是从约40到约100,000的整数;
R1到R6独立地选自:
a)取代或未取代的烷基、烷氧基、芳基、芳氧基、甲硅烷基、甲硅烷氧基、烷基磺酰基、烷基氨基、二烷基氨基、脲基、羧酸酯、烷基单脒、烷基双脒、烷氧基单脒或烷氧基双脒;或氨基;
b)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂环烷基;
c)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂芳基;
d)核苷酸或核苷酸残基;
e)生物大分子;或
f)嘧啶或嘌呤碱基;以及
允许足够的时间使创伤愈合。
所有在本公开中提到的出版物和专利,为了描述和公开的目的在此以其全文引为参考,例如在出版物中描述的、可以与本发明描述的方法、组合物、物品和工艺结合使用的构建物和方法。提供在整个文本中讨论的出版物,仅仅是因为其公开在本申请的提交日期之前。本文中没有一处将被解释为承认本发明人没有权利因为在先发明而使本公开内容在日期上据先。如果任何被合并引为参考的参考文献中使用的用法或术语与本公开中使用的用法或术语冲突,以本公开的用法和术语为准。提供了本公开的摘要以满足37C.F.R.§1.72的要求和37CF.R.§1.72(b)中陈述的目的,“一般要能够使美国专利和商标局与公众从粗略浏览中快速确定技术性公开内容的性质和要点”。摘要不打算用于解释随附的权利要求书的范围或限制本文公开的主题内容的范围。此外,任何标题也不打算用于解释随附的权利要求书的范围或限制本文公开的主题内容的范围。为了描述本来被指定为解释性或预言性实施例而使用的任何过去时态,不打算反映所述解释性或预言性实施例已经被实际执行。
除非另有指明,否则当公开或宣称任何类型的范围、例如分子量、层厚度、浓度、温度等的范围时,它打算各个公开或宣称这样的范围能够合理地涵盖的每个可能数字,包括其中涵盖的任何子范围。例如,当申请人公开或宣称具有一定数量的原子、例如碳原子的化学部分时,申请人的意图是各个公开或宣称这样的范围能够涵盖的、与本文的公开内容相符的每个可能数字。因此,通过公开烷基取代基或基团可以具有1到20个碳原子,申请人的意图是列举具有1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个碳原子、包括其中涵盖的任何范围或子范围的烷基。因此,如果出于任何原因申请人选择要求少于公开内容的整个范围的权利,例如,以应对当提交申请时申请人尚未意识到的参考文献时,申请人保留了将可以根据范围或任何类似方式要求权利的这种组中的任何单个成员、包括组中任何子范围或子范围的组合限制或排除出去的权利。
实施例
实施例1
在一个实施方案中,可通过如下的浸涂方法制备基质的薄膜。为了在任意基材上生产超薄薄膜,可以使用可编程的浸涂过程。可以将预先清洁和用粘附促进剂预先处理的基材,在各种不溶剂中浓度为0.5到50mg/ml的溶液中浸泡0-5分钟的时间,然后可以用50μm/s直至50mm/min的速度将它们从溶液中撤出。在取出样品后,可以使用任选的在40-80℃10-30分钟的加热固化步骤来实现残余溶剂的去除。如此产生的薄膜表现出从约0到约1.0μm和从约0-0.5μm的厚度。
实施例2
在一个实施方案中,可通过如下的旋涂方法制备基质的薄膜。为了在平坦的基材上产生均匀超薄的薄膜,可以使用旋涂程序。可以将预先清洁和用粘附促进剂预先处理的基材放置在旋涂装置中央,将在各种溶剂中浓度为0.5到50mg/ml的溶液0.1到0.5ml铺展在基材上。在1-10秒的停留时间后,可以执行从10rpm逐渐升至1000rpm以实现溶液的均匀铺展,然后在1-10秒的间隔时间中线上升到1000-2000rpm的目标,使薄膜进一步变薄。最后可以在5-120秒停留时间后进行最终上升到2000-4000rpm来达到所需的薄膜厚度。在取出样品后,可以使用任选的在40-80℃10-30分钟的加热固化步骤来实现残余溶剂的去除。如此产生的薄膜表现出从约0-0.5μm的厚度。
实施例3
在一个实施方案中,可通过如下的喷涂方法制备基质的薄膜。可以使用可编程的注射泵向具有0.5mm孔口的气动双进料同轴喷嘴供应不同溶剂共混物中的溶液。的浓度范围为0到20mg/ml,并可以用1-5ml/min的速度供应给喷嘴。取决于溶液的粘度,可以通过1.0-4.5巴的压力方案实现雾化。在实验中样品距离可以在0-40cm之间变化。取决于所使用的喷涂时间长度,所得到的薄膜表现出从约1.0到约100μm的厚度。
实施例4
在一个实施方案中,可通过如下的相分离方法制备膜。与适合的溶剂能够在升高的温度下形成均质溶液,该溶液在冷却后显示出混溶性间隙,并能够导致聚合物的沉淀。适合的组合的实例包括与乙二醇二甲醚、叔丁基甲基醚、辛酸乙酯或环己酮。在超饱和的溶液与这些溶剂冷却的过程中,可以形成凝胶状层。
示例性配方:a)可以将10-100mg在回流(沸点)条件下溶解在1-10ml叔丁基甲基醚中;以及b)将10-100mg在80℃下溶解在1-10ml辛酸乙酯中。在饱和溶液冷却到环境温度的过程中,可以形成略微不透明的凝胶状层。通过例如用非溶剂进行逐渐溶剂置换(使用低温萃取步骤)或通过超临界点干燥(现有工艺技术),可以进一步获得作为高度多孔固体的凝胶层。所得到的膜表现出从约0.1到约100μm的厚度。
实施例5
在一个实施方案中,可通过如下的相分离方法制备膜。挥发性溶剂从两种(溶剂/)或三种组分(溶剂/沉淀剂)的均质共混物中受控蒸发,能够导致聚合物富集相的沉淀。在三组分混合物中,所选的沉淀剂通常是挥发性较低的非溶剂。沉淀可以通过蒸发挥发性溶剂来诱导,这时溶剂混合物逐渐变得富集有沉淀剂。适合的组合的实例包括和丙酮、THF或乙酸乙酯,用于典型的溶剂流延薄膜。取决于蒸发速度和浓度,上述实例能够给出从略微有孔直到完全闭孔的透明球粒状薄膜。适合的三组分混合物包括和丙酮/异丙醇或乙酸乙酯/异丙醇共混物或任何其他适合的溶剂/非溶剂混合物。通过这种方法制备的膜可以形成具有多孔到具纤维特征的不透明薄膜。所得到的膜表现出从约0.1到约100μm的厚度。
实施例6
通过相分离方法制备膜——从两种或多种组分的均质溶液蒸发挥发性溶剂
在一个实施方案中,可通过如下的相分离方法制备膜。测试了双组分混合物(典型的溶剂流延薄膜):/丙酮;/THF;和/乙酸乙酯。测试的浓度范围是0.5-2(w/v)%/溶剂。取决于蒸发速度和浓度,上述实例能够给出从略微多孔直到完全闭孔的透明球粒状薄膜。所得到的膜表现出从约0.1到约100μm的厚度。
实施例7
通过相分离方法制备膜——从两种或多种组分的均质溶液蒸发挥发性溶剂
在一个实施方案中,可通过如下的相分离方法制备膜。示例性配制:a)通过在环境温度下的缓慢溶剂蒸发,从2(w/v)%的丙酮溶液沉积双组分溶剂流延膜;以及b)通过在环境温度下的缓慢溶剂蒸发,从2(w/v)%的乙酸乙酯溶液沉积双组分溶剂流延膜。通过该方法制备的膜通常形成具有多孔到纤维状或球粒状、无孔特征的不透明薄膜。所得到的膜表现出从约0.1到约100μm的厚度。
实施例8
通过相分离方法制备膜——从两种或多种组分的均质溶液蒸发挥发性溶剂
在一个实施方案中,可通过如下的相分离方法制备膜。测试了三组分混合物:/丙酮/异丙醇;和乙酸乙酯/异丙醇。测试的浓度范围是0.5-2(w/v)%/溶剂,或任何其他适合的溶剂/非溶剂混合物。通过该方法制备的膜通常可以形成具有多孔到纤维状特征的不透明薄膜。所得到的膜表现出从约0.1到约100μm的厚度。
其他示例配制:a)通过在环境温度下的缓慢蒸发,从2(w/v)%在15∶85(v/v)IprOH/EtOAc非溶剂/溶剂混合物中的溶液沉积三组分溶剂流延膜;以及b)通过在环境温度下的缓慢蒸发,从2(w/v)%在20∶80(v/v)IprOH/丙酮非溶剂/溶剂混合物中的溶液沉积三组分溶剂流延膜。所得到的膜表现出从约0.1到约100μm的厚度。
实施例9
通过相分离方法制备膜——向均质溶液添加非溶剂或非溶剂混合物
在一个实施方案中,可通过如下的相分离方法制备膜。可以向均质溶液添加非溶剂/混合物,直到发生相分离。非溶剂也可以在气体状态引入,从而在溶液中非常缓慢地富集其自身。溶剂/非溶剂组合的实例包括和丙酮/水(g/l)、乙酸乙酯/乙醇或二甲基乙酰胺/HCl(g)。其他典型的非溶剂包括甲醇、异丙醇、乙醚、己烷等。
测试的其他溶剂/非溶剂组合的实例:PzF/丙酮/水(g)或(l);PzF/乙酸乙酯/乙醇;和PzF/二甲基乙酰胺/HCl(g)。测试的浓度范围:0.5-2(w/v)%/溶剂。其他典型的非溶剂包括甲醇、异丙醇、乙醚、己烷等。
其他示例性配制:a)通过在环境温度下存在饱和水蒸汽的情况下缓慢蒸发,从2(w/v)%PzF的乙酸异戊酯溶液沉积溶剂流延的PzF膜;以及b)通过在存在饱和水蒸汽气氛的情况下缓慢蒸发,从2(w/v)%PzF的丙酮溶液产生溶剂流延的PzF膜,取下膜,随后通过溶剂焊接技术使用乙酸乙酯蒸气附着到基材层上。
实施例10
通过相分离方法制备膜——通过快速溶剂蒸发制备多孔闭孔膜
示例性配制:在高压釜中装入1g和25g利用液氮冷凝的乙醚。饱和溶液可以通过实施例3中描述的同轴喷嘴来铺展,用于随后的喷涂施加,以在喷涂靶区域上直接获得膜。或者,可以将压缩气体排气以直接在高压釜中获得铺展开的膜。
实施例11
在一个实施方案中,可通过如下的相分离方法制备膜。可以通过电纺0.5-20mg/ml聚合物的乙酸乙酯溶液来产生纳孔、中孔和微孔的无纺具纤维垫。带电荷的钝针(1-10kV正电压)可以通过注射泵以0.1-10ml/h的速度进料纺丝溶液。产生的纤维流可以导向距离为0-20cm的已接地的靶,例如支架、铝箔或任何其他适合的导电靶。接地的基材可以是芯轴、平坦或弯曲的物体,例如箔、衬垫、海绵、泡沫、网、纱布,可以是连续或半连续的、多孔和/或任何其他任意形状和性质的。基材、喷嘴或二者可以用任意方式相对于彼此移动,以获得例如纺织或无纺样式或任何具体应用所需的其他样式。得到的膜可以使用稀酸溶液从金属基材上脱离以获得自支撑(free-standing)的膜,或通过施加溶剂蒸气与所讨论基材更牢固地结合(“溶剂焊接技术”)。
实施例12
用于在贴片形式中测试MFWDM效力的体内实验设计
可以进行下面的实验来测试式I所包括的聚合物的效力。用于评估效力的处理组可以包括:(1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料。
对于比较研究来说,用于评估带有式I聚合物的多功能创伤护理敷料基质与竞争性产品的处理组可以包括处理组:1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料,以及示例性竞争产品。
可以将体重和年龄相似的小鼠麻醉,可以通过用剪毛器剃除毛发在动物的两侧暴露出皮肤。在适当清洗后,可以在实验动物的脊柱旁和胸部区域,使用剃刀的切削边缘制造10-15个测得深度为0.3mm的7mm x 10mm矩形创伤部位,或直径5mm的创伤。该技术能够提供表皮和大部分浅层真皮的完全移除,留下完整的表皮附件。每个创伤可以指派给四个处理组之一和示例性竞争产品。然后可以在第1、3、5、7和14天时从代表每个处理组的处死动物上切下创伤并进行分析。创伤包含足够但恒定量的周围边缘皮肤组织量,并具有足够深度以确保肉芽组织可以被分离和取出。然后可以将切下的组织冷冻在液氮中,并包埋在用于组织学评估的组织冷冻介质中。新鲜切下的创伤组织可以放置在膜上,并用一次性使用的手术刀对切开。然后可以使用适合的化合物产生冷冻模块(cryomold)并放置在干冰上,然后可以将模块放置在包埋介质中,在-80℃下储存直到使用。组织学分析可以包括存在的胶原蛋白的积累和免疫组织分型、肉芽组织的血管化和速度、上皮形成速度和瘢痕形成速度。也可以使用来自创伤的样品、引物组和从正常皮肤分离的RNA,使用由Chomezynski和Sacchi概述的程序(Chomezynski,P.和Sacchi,N.,Single-step method of RNA isolation by acid guanidinium thicyanate-phenol-chloroform extraction.(通过酸性硫氰酸胍-苯酚-氯仿抽提分离RNA的一步方法)Anal.Biochem.162,156-159,1987),进行RNA分析。从RNA分析可以确定几种用于愈合介导物的表达趋势(expression lends),包括微血管血液流动、一氧化氮合成酶、内皮素、内皮素受体、血管内皮生长因子、角质细胞生长因子和碱性成纤维细胞生长因子。创伤尺寸的简单测量可用于确定对于每个处理组来说90%的创伤愈合所预期的时间。然后可以进行统计学分析以确定处理组之间的显著性。
实施例13
用于测试MFWDM治疗烧伤的效力的体内实验设计
可以进行下面的实验来测试式I所包括的聚合物的效力。用于评估效力的处理组可以包括:(1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料。
对于比较性研究来说,用于评估带有式I聚合物的多功能创伤护理敷料基质与竞争性产品的处理组可以包括处理组:1)无创伤敷料,(2)带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料,以及示例性竞争产品。可以将12只6周龄雄性Sprague-Dawley大鼠(250g-275g)麻醉,然后用剪毛器剃除动物背部的毛发,跟着用95%乙醇清洗皮肤。可以将黄铜块或杆(2cm x 2cm x 4cm)通过浸泡在严格控制在80℃的沸水中来预热。显然任何尺寸或金属合金可以用来产生所需面积的伤口。可以提起背部皮肤皱褶,将两个块施加到皮肤皱褶的相对侧,按照需要制造灼伤区域,使用Meeh′s公式计算,4cm2、6cm2和8cm2的总灼伤面积代表约8、12和16%的总身体面积。可以将皮肤皱褶压住15秒以产生整个厚度(III级)皮肤灼伤,在动物的脊柱旁和胸部区域可以制造2-5个创伤部位。使用缝合钉将创伤敷料的最外层在向头部和向尾部的边缘处紧固住可能是理想的,然后包扎起来以防止敷料随着动物的运动而迁移。可以将动物以72小时的间隔处死,进行15天。可以使用创伤部位的活组织检查,通过检查红斑、脓或通过真皮内含细菌的中性粒细胞的显微镜检查来确定感染,也可以使用血液来测量感染菌落计数。可以使用显微镜观察上皮重新形成,通过在每个时间点测量新生表皮的长度以允许甚至对于还没有完全重新形成上皮的创伤进行上皮重新形成的程度的定量。也可以对福尔马林固定、乙醇脱水、二甲苯澄清、石蜡包埋的染色切片,使用常规显微术进行组织病理学研究,以确定胶原蛋白的速度和类型、肉芽组织血管化的速度、细菌从创伤的清除、缩小的速度和瘢痕形成的程度。此外,可以在处死时使用测量装置评估创伤的尺寸,以确定对于每个处理组来说90%的创伤愈合所预期的时间。然后可以进行统计学分析以确定处理组之间的显著性。
实施例14
用于测试MFWDM治疗溃疡创伤的效力的体内实验设计
可以进行下面的实验来测试式I所包括的聚合物的效力。用于评估效力的处理组可以包括:(1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料。
对于比较研究来说,用于评估带有式I聚合物的多功能创伤护理敷料基质与竞争性产品的处理组可以包括处理组:1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料,以及示例性竞争产品。可以将十四烷基硫酸钠(STD)皮内注射液注射到40只豚鼠的侧面皮肤中,由此产生了尺寸和形状可重复的浅表溃疡。然后可以将溃疡用处理组敷料处理,在施行后第5、10、30和60天处死动物后进行评估。敷料可以使用缝合钉或包扎物紧固,以防止敷料随着动物的运动而迁移。可以使用处死时从测试动物获得的组织活体样本,来确定血管形成、肉芽组织形成、细菌清除、胶原蛋白的类型或组织、上皮重新形成速度、瘢痕形成程度、白细胞浸润、透皮氧张力和通往创伤和创伤附近的血流的组织病理学。也可以使用来自创伤的样品、引物组和从正常皮肤分离的RNA,使用由Chomezynski和Sacchi概述的程序(Chomezynski,P.和Sacchi,N.,Single-step method of RNA isolation by acid guanidinium thicyanate-phenol-chloroform extraction(通过酸性硫氰酸胍-苯酚-氯仿抽提分离RNA的一步方法).Anal.Biochem.162,156-159,1987),进行RNA分析。从RNA分析可以确定用于愈合的几种介导物的表达趋势(expression lends),包括微血管血液流动、一氧化氮合成酶、内皮素、内皮素受体、血管内皮生长因子、角质细胞生长因子和碱性成纤维细胞生长因子。创伤尺寸的简单测量可用于确定对于每个处理组来说90%的创伤愈合所预期的时间。然后可以进行统计学分析以确定处理组之间的显著性。
实施例15
用于测试MFWDM治疗严重的深组织创伤效力的体内实验设计
可以进行下面的实验来测试式I所包括的聚合物的效力。用于评估效力的处理组可以包括:(1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料。
对于比较性研究来说,用于评估带有式I聚合物的多功能创伤护理敷料基质与竞争产品的处理组可以包括处理组:1)无创伤敷料,(2)带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料,以及示例性竞争产品。可以将8只白色幼家猪麻醉,并可以通过用剪毛器剃除毛发并用95%乙醇清洗在动物两侧产生创伤。在适当清洗后,可以在试验动物的脊柱旁和胸部区域,使用剃刀的切削边缘制造30-50个测得深度为1.0mm的7mm x 10mm矩形创伤部位。然后可以在第1、5、10和20天时从来自每个处理组的处死动物上切下一组创伤并进行分析。创伤包含足够但恒定量的周围边缘皮肤组织量,并具有足够深度以确保肉芽组织可以被分离和取出。然后可以将切下的组织冷冻在液氮中,并包埋在用于组织学的组织冷冻介质中。新鲜切下的创伤组织可以放置在膜上,并用一次性手术刀对切开。然后可以使用适合的化合物产生冷冻模块并放置在包埋介质中,在-80℃下储存直到使用。组织学分析可以包括存在的胶原蛋白的积累和免疫组织学分型、肉芽组织的血管化和速度、上皮形成速度、透皮氧张力、组织坏死和瘢痕形成速度。也可以使用来自创伤的样品、引物组和从正常皮肤分离的RNA,使用由Chomezynski和Sacchi概述的程序(Chomezynski,P.和Sacchi,N.,Single-step method of RNA isolation by acid guanidinium thicyanate-phenol-chloroform extraction.(通过酸性硫氰酸胍-苯酚-氯仿抽提分离RNA的一步方法)Anal.Biochem.162,156-159,1987),进行RNA分析。从RNA分析可以确定用于愈合的几种介导物的表达趋势,包括微血管血液流动、一氧化氮合成酶、内皮素、内皮素受体、血管内皮生长因子、角质细胞生长因子和碱性成纤维细胞生长因子。创伤尺寸的简单测量可用于确定对于每个处理组来说90%的创伤愈合所预期的时间。然后可以进行统计学分析以确定处理组之间的显著性。
实施例16
用于测试MFWDM治疗坏死性组织创伤效力的体内实验设计
可以进行下面的实验来测试包含在式I中的聚合物的效力。用于评估效力的处理组可以包括:(1)无创伤敷料,(2)不带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料。
对于比较性研究来说,用于评估带有式I聚合物的多功能创伤护理敷料基质与竞争产品的处理组可以包括处理组:1)无创伤敷料,(2)带有式I聚合物的多功能创伤护理敷料基质敷料,(3)带有浓度A的式I聚合物的多功能创伤护理敷料基质敷料,(4)带有浓度B的式I聚合物的多功能创伤护理敷料基质敷料,以及示例性竞争产品。可以将两只无特定病原体的雌性约克夏(Yorkshire)猪(12-15kg)麻醉,从脊柱旁和胸部区域的背面皮肤剃除毛发,并将暴露的皮肤用95%乙醇清洗。可以使用6mm活检咬切器(biopsy punch)(0.5mm深)产生21个全厚度的切割创伤。可以从对照组获取活组织样本,为评估初始创伤参数提供基线。创伤可以用来自处理组的敷料覆盖,并在第2和4天温和清洁,并重新施加敷料。可以在第5和10天处死后进行分析。创伤可以通过肉眼检查,对流体积累、周围正常皮肤的外观、被清创过的组织的样子、创伤焦痂的清除和伴发流血(punctuate bleeding)进行临床评估。从所有提供了创伤深横截面的创伤取出的活组织样本可以被固定、安装,并用苏木精、曙红和elastochrome染色。然后可以对切片进行显微镜评价,评价清创和愈合的指征。这可以包括坏死性焦痂或纤维蛋白性结块的清除、表皮迁移和成熟、炎性细胞、细胞外基质、新血管、和愈合的整体评估。对于每个处理组,可以根据绝对尺度或相对于未处理对照赋予分值。然后可以进行统计学分析以确定处理组之间的显著性。
上面用于解释目的的描述,使用了专用术语以提供对本发明的充分理解。但是,显然,对于本技术领域的专业人员来说,为了实践本发明并不需要具体的详细描述。提出上述对本发明具体实施方案的描述的目的是为了说明和描述。它们不打算是穷举的,或将本发明限制于所公开的精确形式。显然,根据上面的讲授,许多修改和改变是可能的。实施方案的显示和描述是为了最好地解释本发明的原理及其实际应用,从而使本技术领域的其他专业人员能够最好地利用本发明以及各种不同的实施方案进行适合于所考虑的具体应用的各种不同修改。本发明的范围打算由下面的权利要求书及其等同体来定义。
Claims (19)
2.权利要求1的多功能创伤护理敷料基质,其中至少一个R1到R6取代基是用至少一个氟原子取代的烷氧基。
3.权利要求1的多功能创伤护理敷料基质,其中至少一个R1到R6取代基选自:OCH3、OCH2CH3、O(CH2)2CH3、O(CH2)3CH3、O(CH2)4CH3、O(CH2)5CH3、OCF3、OCH2CF3、OCH2CH2CF3、OCH2CF2CF3、OCH(CF3)2、OCCH3(CF3)2、OCH2CF2CF2CF3、OCH2(CF2)3CF3、OCH2(CF2)4CF3、OCH2(CF2)5CF3、OCH2(CF2)6CF3、OCH2(CF2)7CF3、OCH2CF2CHF2、OCH2CF2CF2CHF2、OCH2(CF2)3CHF2、OCH2(CF2)4CHF2、OCH2(CF2)5CHF2、OCH2(CF2)6CHF2和OCH2(CF2)7CHF2。
4.权利要求1的多功能创伤护理敷料基质,其中1%或以下的R1到R6取代基是烯氧基。
5.权利要求1的多功能创伤护理敷料基质,其中式(I)的聚磷腈聚合物具有至少2,000,000g/mol的分子量。
6.权利要求1的多功能创伤护理敷料基质,其中式(I)的聚磷腈聚合物在基材层的至少组织接触表面上部分或完全地形成包层。
7.权利要求1的多功能创伤护理敷料基质,其中基材层包含下列一种或多种:合成聚合物,聚合物共混物,嵌段聚合物,嵌段聚合物的共混物,天然存在的植物来源材料,改性的植物来源材料和改性的动物来源材料。
8.权利要求1的多功能创伤护理敷料基质,其中基材层选自:纺织织物层、无纺织物层、多孔薄膜、无孔薄膜、多孔膜、无孔膜、开孔泡沫、闭孔泡沫、纺织垫、无纺垫、网状物、衬垫、海绵、泡沫、海绵和纱布。
9.权利要求1的多功能创伤护理敷料基质,其中基材层还包含含有目标药剂的囊。
10.权利要求9的多功能创伤护理敷料基质,其中所述囊具有约10μm到约1200μm的平均直径大小。
11.权利要求1的多功能创伤护理敷料基质,其中基材层是泡沫海绵。
12.权利要求11的多功能创伤护理敷料基质,其还包含从基材层的组织接触表面移除过量体液的管式部件。
13.权利要求1的多功能创伤护理敷料基质,其中基材层与选自下列的创伤部位接触:割伤,砍伤,开放创伤,组织破裂,褥疮,皮炎,病变,慢性创伤,战场创伤,坏死性创伤,急性、慢性、外伤性伤口,擦伤,挫伤,坏死性筋膜炎,中毒性表皮坏死,压伤,静脉机能不全性溃疡,动脉性溃疡,糖尿病性溃疡,神经病理性溃疡,压迫性溃疡,混合型溃疡,烧伤,毛霉菌病,血管炎性创伤和坏疽性脓皮病。
14.权利要求1的多功能创伤护理敷料基质,其还包括一个或多个相对于创伤部位取向时放置在第一个基材层上方的叠加的基材层,其中材料选自下列一种或多种:合成聚合物,聚合物共混物,嵌段聚合物,嵌段聚合物的共混物,天然存在的植物来源材料,改性的植物来源材料和改性的动物来源材料。
15.权利要求14的多功能创伤护理敷料基质,其中叠加的基材层选自:纺织织物层、无纺织物层、多孔薄膜、无孔薄膜、多孔膜、无孔膜、开孔泡沫、闭孔泡沫、纺织垫、无纺垫、网状物、衬垫、海绵、泡沫、海绵和纱布。
16.权利要求14的多功能创伤护理敷料基质,其中基材层是泡沫海绵。
17.权利要求16的多功能创伤护理敷料基质,其还包含从基材层的组织接触表面移除过量体液的管式部件。
19.一种用于创伤愈合的方法,所述方法包括:
用多功能创伤护理敷料基质覆盖创伤部位,所述多功能创伤护理敷料基质包含:
基材层,所述基材层形成为包含至少一个组织接触表面的创伤敷料并掺有至少一种式(I)的高分子量聚磷腈聚合物:
其中
n是从约40到约100,000的整数;
R1到R6独立地选自:
a)取代或未取代的烷基、烷氧基、芳基、芳氧基、甲硅烷基、甲硅烷氧基、烷基磺酰基、烷基氨基、二烷基氨基、脲基、羧酸酯、烷基单脒、烷基双脒、烷氧基单脒或烷氧基双脒;或氨基;
b)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂环烷基;
c)具有至少一个氮、磷、氧、硫或硒作为杂原子的杂芳基;
d)核苷酸或核苷酸残基;
e)生物大分子;或
f)嘧啶或嘌呤碱基;以及
允许足够的时间使创伤愈合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3070708P | 2008-02-22 | 2008-02-22 | |
US61/030,707 | 2008-02-22 | ||
PCT/US2009/034893 WO2009105761A2 (en) | 2008-02-22 | 2009-02-23 | Multi-functional wound dressing matrices and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102036692A true CN102036692A (zh) | 2011-04-27 |
Family
ID=40986253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801128071A Pending CN102036692A (zh) | 2008-02-22 | 2009-02-23 | 多功能创伤敷料基质及相关方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100047324A1 (zh) |
EP (1) | EP2254605A4 (zh) |
CN (1) | CN102036692A (zh) |
WO (1) | WO2009105761A2 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103611182A (zh) * | 2013-12-10 | 2014-03-05 | 东华大学 | 一种医用敷料用核-壳结构超细纤维载体材料的制备方法 |
CN107106735A (zh) * | 2014-12-09 | 2017-08-29 | 加利福尼亚大学董事会 | 新型伤口愈合增强设备 |
CN107854719A (zh) * | 2017-11-17 | 2018-03-30 | 齐齐哈尔医学院 | 一种双载药伤口抗菌敷料及其制备方法 |
CN113242725A (zh) * | 2019-04-24 | 2021-08-10 | 普吉尼科技股份有限公司 | 用于分析体液及伤口相关生物分子的系统 |
CN113384741A (zh) * | 2021-05-21 | 2021-09-14 | 浙江大学 | 一种具有主动与被动双重抗菌机理的季铵盐聚膦腈水凝胶伤口敷料及制备方法 |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
WO2008034031A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
WO2008034048A2 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprosthesis with biostable inorganic layers |
WO2008034013A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
CA2663271A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
WO2008036548A2 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
WO2008083190A2 (en) | 2006-12-28 | 2008-07-10 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
GB0804654D0 (en) | 2008-03-13 | 2008-04-16 | Smith & Nephew | Vacuum closure device |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
RU2018129725A (ru) | 2008-07-18 | 2019-03-20 | Байомод Консептс Инк. | Изделия, высвобождающие активный ингредиент |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
WO2011115828A1 (en) * | 2010-03-13 | 2011-09-22 | Devon Anderson | Absorbent bioabsorbable composite surgical biomaterial |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US20110257611A1 (en) * | 2010-04-16 | 2011-10-20 | Kci Licensing, Inc. | Systems, apparatuses, and methods for sizing a subcutaneous, reduced-pressure treatment device |
EP2417947A1 (en) * | 2010-08-12 | 2012-02-15 | John Bennett | Integrated contoured negative pressure bandages |
US9421132B2 (en) | 2011-02-04 | 2016-08-23 | University Of Massachusetts | Negative pressure wound closure device |
AU2012212070A1 (en) | 2011-02-04 | 2013-09-19 | University Of Massachusetts | Negative pressure wound closure device |
US8487017B2 (en) | 2011-06-27 | 2013-07-16 | Covidien Lp | Biodegradable materials for orthopedic devices based on polymer stereocomplexes |
KR101491053B1 (ko) * | 2012-03-06 | 2015-02-10 | 주식회사 아모그린텍 | 점착 테이프 및 그 제조방법 |
EP2852333B1 (en) | 2012-05-22 | 2021-12-15 | Smith & Nephew plc | Apparatuses for wound therapy |
MX2014014265A (es) | 2012-05-22 | 2015-06-23 | Smith & Nephew | Dispositivo para cierre de heridas. |
CA2777975C (en) * | 2012-05-24 | 2016-06-28 | Ray Arbesman | Contusion tape |
MX2014014325A (es) | 2012-05-24 | 2015-08-06 | Smith & Nephew Inc | Dispositivos y metodos para tratar y cerrar heridas con presion negativa. |
CN104812343B (zh) | 2012-07-16 | 2019-06-18 | 史密夫和内修有限公司 | 负压伤口闭合设备 |
CN105188622A (zh) | 2013-03-13 | 2015-12-23 | 史密夫和内修有限公司 | 负压伤口封闭装置以及用于以负压处理伤口的系统和方法 |
CN105007870B (zh) | 2013-03-14 | 2019-12-13 | 史密夫及内修公开有限公司 | 在利用负压处理伤口中使用的可压缩的伤口填充物、系统和方法 |
CA151026S (en) | 2013-05-08 | 2014-01-03 | Ray Arbesman | Adhesive brace with locating window |
CA151358S (en) | 2013-05-29 | 2014-02-20 | Ray Arbesman | Kinesiology tape strip with release liner grid lines |
AU2014291873B2 (en) | 2013-07-16 | 2019-01-24 | Smith & Nephew Plc | Apparatus for wound therapy |
WO2015061352A2 (en) | 2013-10-21 | 2015-04-30 | Smith & Nephew, Inc. | Negative pressure wound closure device |
US10201642B2 (en) | 2014-01-21 | 2019-02-12 | Smith & Nephew Plc | Collapsible dressing for negative pressure wound treatment |
WO2015110409A1 (en) | 2014-01-21 | 2015-07-30 | Smith & Nephew Plc | Wound treatment apparatuses |
TWD179958S (zh) | 2015-04-20 | 2016-12-01 | 思拜德泰克有限公司 | 縫合帶之離型紙 |
EP4209201A1 (en) | 2015-04-29 | 2023-07-12 | Smith & Nephew, Inc. | Negative pressure wound closure device |
WO2017070017A1 (en) * | 2015-10-23 | 2017-04-27 | Rush University Medical Center | Topical compositions providing pain relief and methods of use thereof |
WO2018041805A1 (en) | 2016-08-30 | 2018-03-08 | Smith & Nephew Plc | Systems for applying reduced pressure therapy |
US11096832B2 (en) | 2016-09-27 | 2021-08-24 | Smith & Nephew Plc | Wound closure devices with dissolvable portions |
WO2018085457A1 (en) | 2016-11-02 | 2018-05-11 | Smith & Nephew Inc. | Wound closure devices |
US10517989B1 (en) | 2016-11-23 | 2019-12-31 | Jonathan F. Arnold | Enhanced medical dressing apparatus, system, and method |
US10548948B2 (en) | 2017-03-02 | 2020-02-04 | The United States Of America As Represented By The Secretary Of The Navy | Methods of treating fungal infections |
US11524051B2 (en) | 2017-03-02 | 2022-12-13 | The United States Of America As Represented By The Secretary Of The Navy | Methods of treating fungal infections |
WO2018229010A1 (en) | 2017-06-13 | 2018-12-20 | Smith & Nephew Plc | Collapsible structure and method of use |
EP3638168A1 (en) | 2017-06-13 | 2020-04-22 | Smith & Nephew PLC | Wound closure device and method of use |
EP3638173A1 (en) | 2017-06-14 | 2020-04-22 | Smith & Nephew, Inc | Control of wound closure and fluid removal management in wound therapy |
AU2018284233B2 (en) | 2017-06-14 | 2024-01-04 | Smith & Nephew, Inc. | Fluid removal management and control of wound closure in wound therapy |
EP3638170B1 (en) | 2017-06-14 | 2024-03-13 | Smith & Nephew PLC | Collapsible structure for wound closure and method of use |
AU2018285239B2 (en) | 2017-06-14 | 2023-09-21 | Smith & Nephew Plc | Collapsible sheet for wound closure and method of use |
US11607344B2 (en) | 2017-07-27 | 2023-03-21 | Smith & Nephew Plc | Customizable wound closure device and method of use |
WO2019030136A1 (en) | 2017-08-07 | 2019-02-14 | Smith & Nephew Plc | WELD CLOSURE DEVICE WITH PROTECTIVE LAYER AND METHOD OF USE |
WO2019042790A1 (en) | 2017-08-29 | 2019-03-07 | Smith & Nephew Plc | SYSTEMS AND METHODS FOR MONITORING WOUND CLOSURE |
WO2020124038A1 (en) | 2018-12-13 | 2020-06-18 | University Of Massachusetts | Negative pressure wound closure devices and methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1665550A (zh) * | 2002-07-05 | 2005-09-07 | 保利詹尼克斯有限公司 | 输送和释放药物活性剂的植入物及其制备方法 |
US20050256437A1 (en) * | 2001-11-23 | 2005-11-17 | Derek Silcock | Absorbent wound dressing containing a hydrogel layer |
US20060182787A1 (en) * | 2003-07-08 | 2006-08-17 | Beiersdorf Ag | Skin or wound pad containing encapsulated substances which promote the healing of wounds and/or are used for skin care |
US20070185426A1 (en) * | 2001-02-16 | 2007-08-09 | Kci Licensing, Inc. | Biocompatible wound dressing |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4969880A (en) * | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
ES2186085T3 (es) * | 1994-08-22 | 2003-05-01 | Kinetic Concepts Inc | Recipiente de drenaje de heridas. |
US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
DE19743373A1 (de) * | 1997-09-30 | 1999-04-15 | Univ Heidelberg | ·3··2·P-Polyphosphazen |
EP1179353A1 (de) * | 2000-08-11 | 2002-02-13 | B. Braun Melsungen Ag | Antithrombogene Implantate mit Beschichtung aus Polyphosphazenen und einem pharmakologisch aktiven Wirkstoff |
US7070584B2 (en) * | 2001-02-20 | 2006-07-04 | Kci Licensing, Inc. | Biocompatible wound dressing |
DE10113971A1 (de) * | 2001-03-22 | 2002-10-24 | Polyzenix Gmbh | Verfahren zur Beschichtung von Oberflächen aus Kunststoff mit Bis-Poly-Trifluorethoxy-Polyphosphazen und Derivaten |
CA2457018C (en) * | 2001-08-17 | 2010-12-14 | Polyzenix Gmbh | Device based on nitinol, a process for its production and its use |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US20050136093A1 (en) * | 2002-07-05 | 2005-06-23 | Polyzenix Gmbh | Implant for transport and release for pharmacologically active agents as well as a process for producing the same |
US7235295B2 (en) * | 2003-09-10 | 2007-06-26 | Laurencin Cato T | Polymeric nanofibers for tissue engineering and drug delivery |
BRPI0717739A2 (pt) * | 2006-10-10 | 2014-07-29 | Celonova Biosciences Inc | Dispositivo médico, método para fabricação deste e método para aumentar a biocompatibilidade de um dispositivo médico |
CN102176868A (zh) * | 2008-02-11 | 2011-09-07 | 西洛诺瓦生物科学公司 | 组织紧固物品和装置以及相关方法 |
-
2009
- 2009-02-23 EP EP09713600A patent/EP2254605A4/en not_active Withdrawn
- 2009-02-23 CN CN2009801128071A patent/CN102036692A/zh active Pending
- 2009-02-23 WO PCT/US2009/034893 patent/WO2009105761A2/en active Application Filing
- 2009-02-23 US US12/391,040 patent/US20100047324A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070185426A1 (en) * | 2001-02-16 | 2007-08-09 | Kci Licensing, Inc. | Biocompatible wound dressing |
US20050256437A1 (en) * | 2001-11-23 | 2005-11-17 | Derek Silcock | Absorbent wound dressing containing a hydrogel layer |
CN1665550A (zh) * | 2002-07-05 | 2005-09-07 | 保利詹尼克斯有限公司 | 输送和释放药物活性剂的植入物及其制备方法 |
US20060182787A1 (en) * | 2003-07-08 | 2006-08-17 | Beiersdorf Ag | Skin or wound pad containing encapsulated substances which promote the healing of wounds and/or are used for skin care |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103611182A (zh) * | 2013-12-10 | 2014-03-05 | 东华大学 | 一种医用敷料用核-壳结构超细纤维载体材料的制备方法 |
CN103611182B (zh) * | 2013-12-10 | 2015-05-13 | 东华大学 | 一种医用敷料用核-壳结构超细纤维载体材料的制备方法 |
CN107106735A (zh) * | 2014-12-09 | 2017-08-29 | 加利福尼亚大学董事会 | 新型伤口愈合增强设备 |
CN107854719A (zh) * | 2017-11-17 | 2018-03-30 | 齐齐哈尔医学院 | 一种双载药伤口抗菌敷料及其制备方法 |
CN113242725A (zh) * | 2019-04-24 | 2021-08-10 | 普吉尼科技股份有限公司 | 用于分析体液及伤口相关生物分子的系统 |
CN113242725B (zh) * | 2019-04-24 | 2023-03-28 | 普吉尼科技股份有限公司 | 用于分析体液及伤口相关生物分子的系统 |
CN113384741A (zh) * | 2021-05-21 | 2021-09-14 | 浙江大学 | 一种具有主动与被动双重抗菌机理的季铵盐聚膦腈水凝胶伤口敷料及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2009105761A2 (en) | 2009-08-27 |
EP2254605A4 (en) | 2012-06-20 |
WO2009105761A3 (en) | 2009-11-26 |
EP2254605A2 (en) | 2010-12-01 |
US20100047324A1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102036692A (zh) | 多功能创伤敷料基质及相关方法 | |
Dias et al. | Advances in electrospun skin substitutes | |
Wang et al. | Insulin-loaded silk fibroin microneedles as sustained release system | |
Zhang et al. | Microneedle system for tissue engineering and regenerative medicine | |
Pal et al. | Nano-/microfibrous cotton-wool-like 3D scaffold with core–shell architecture by emulsion electrospinning for skin tissue regeneration | |
CN101970021B (zh) | 包含活性成分的明胶海绵、其制备及用途 | |
EP2276879B1 (en) | Electrospun dextran fibers and devices formed therefrom | |
US20230120449A1 (en) | Device, systems, and methods of applying a treatment solution to a treatment site | |
Pleguezuelos-Beltrán et al. | Advances in spray products for skin regeneration | |
Lyu et al. | Going below and beyond the surface: Microneedle structure, materials, drugs, fabrication, and applications for wound healing and tissue regeneration | |
CN102573790B (zh) | 用于产生白介素‑1受体拮抗剂的可植入装置 | |
KR20170118198A (ko) | 지혈 조성물 및 지혈 장치 (변이체) | |
TW200938235A (en) | Improved reduced pressure dressing coated with biomolecules | |
Arora et al. | Platelet‐rich plasma—Where do we stand today? A critical narrative review and analysis | |
TWI640306B (zh) | 薄膜及其製造方法 | |
CN107106722A (zh) | 伤口敷料装置 | |
US20050129732A1 (en) | Biodegradable, antibiotic, controlled release tape | |
US20220040378A1 (en) | Wound care treatment and methods of making and using same | |
AU2014348720B2 (en) | Hemostatic products | |
EP2667791B1 (en) | Barbs for fixation of biologic plastics | |
Simpson et al. | Biomaterials for hemostasis | |
Lee et al. | Promoting diabetic wound therapy using biodegradable rhPDGF-loaded nanofibrous membranes: CONSORT-compliant article | |
US20220249732A1 (en) | Electrospun dextran fibers and devices formed therefrom | |
Wu et al. | Incorporation of protein-loaded microspheres into chitosan-polycaprolactone scaffolds for controlled release | |
KR101495449B1 (ko) | 혈소판 패치의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110427 |